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Abstract 
Diabetes mellitus is characterized by hyperglycemia and there are three main types: 
type I, type II and gestational. The prevalence of diabetes is increasing and all patients with 
type I diabetes, and about 35% of type II diabetics require insulin therapy. When insulin is 
administrated by subcutaneous injection, every tissue are exposed to the same 
concentration and only a fraction of the injected dose is delivered to the liver. NP (NP) have 
been considered for oral insulin delivery by stabilizing and ensuring its biological activity in 
vivo and by facilitating intestinal delivery and absorption. Thus, the insulin delivered by the 
NP mimic the endogenous insulin.  The aim of this work was study the biodistribution of the 
NP, therefore the biodistribution of 99mTc-BSA(bovine serum albumin) and 99mTc-BSA-NP 
was carried out after the BSA and BSA-NP radiolabeling and a quality control procedure was 
developed and optimized. 
NP were formulated by emulsification/internal gelation, which nucleus consists of 
alginate, dextran sulfate, calcium carbonate and insulin following complexation with chitosan 
and coated with BSA. To optimize radiolabelling procedure of BSA, different parameters 
were tested, namely, ligand and reducing agent concentration, pH, radionuclide activity, 
temperature and incubation time. To optimize the quality control of the radiolabeling 
procedure different mobile phases and stationary phases was tested. To evaluate 
radiopharmaceuticals biodistribution, a comparative study between 99mTc-BSA and 99mTc-
BSA-NP was developed. The complexes were administered by gavage in Balb/c mice. The 
animals were killed at different time intervals: 0, 30, 60, 90, 120, 180, 360 and 1440 minutes 
after administration. Gastrointestinal tract and several organs and fluids were collected. 
Furthermore, the gastrointestinal content was separated from the gastrointestinal wall, 
whose was cleaned. All biological material collected was weighed and its radioactivity was 
evaluated by image processing. The percent of administered activity per milligram of organ 
was calculated. 
Radiochemical purity was determined by two systems with strips of instant thin-layer 
chromatography-silica gel (ITLC-SG) as stationary phase and NaCl (sodium chlorate) and 
ACD (acid citrate-dextrose) as mobile phases. The radiochemical purity obtained was higher 
than 95% and remain stable at least for 6h. These results were obtained by using: sodium 
thiosulfate 10mg.ml-1; HCl (hydrochloric acid), N; BSA 10mg.ml-1; phosphate buffer (pH 7.4) 
(1.0/1.0/2.5/2.0) (v/v/v/v) and 1110 to 2220 MBq of Na99mTcO4
- (sodium perthecnetate). The 
biodistribution studies revealed that 99mTc-BSA-NP have different profiles of adhesion to the 
stomach and small intestine epithelium regardless of the profile of the contents’ progression 
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in the gut, comparatively to the 99mTc-BSA biodistribution. Six hours after administration 
most of the complex was in the large intestine and all the activity was eliminated 24h after 
administration.   
The labelling procedure of BSA was stable, reproducible and reveals potential to 
track albumin. Differences between 99mTc-BSA-NP and 99mTc-BSA seem to do due to the 
mucoadhesive properties of the NP’ polymers, namely chitosan. However, to evaluate insulin 
absorption future studies should be carried out. 
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Resumo 
A diabetes mellitus é caracterizada por hiperglicemia e a doença manifesta-se em 
diferentes tipos, sendo os principais, o tipo 1, o tipo 2 e a gestacional. A prevalência da 
diabetes tem aumentado e todos os doentes com diabetes tipo I e cerca de 35% dos 
diabéticos tipo 2 têm de recorrer à terapia com insulina. A insulina administrada pela via 
subcutânea leva a uma exposição de todos os tecidos à mesma concentração da insulina e 
apenas uma fracção da dose injectada é captada pelo fígado. As nanopartículas (NP) para 
administração oral da insulina têm vindo a ser consideradas por assegurarem e estabilizarem 
a sua actividade biológica in vivo, mas também por facilitarem a sua entrega e absorção em 
meio intestinal. Desta forma, a insulina administrada com recurso às nanopartículas 
mimetizaria a insulina endógena.  
O objectivo deste trabalho era estudar a biodistribuição das nanoparticulas, para tal 
procedeu-se ao estudo da biodistribuição do 99mTc-BSA(bovine serum albumin) e do 99mTc-
BSA-NP, após o desenvolvimento e optimização do controlo de qualidade e da marcação 
radioactiva do BSA e do BSA-NP.  
As nanopartículas foram produzidas por emulsificação/gelação interna, o seu núcleo é 
constituído por alginato, sulfato de dextran, carbonato de cálcio e insulina, sofre 
complexação com o quitosano e é revestido por BSA. Relativamente à optimização do 
controlo de qualidade do procedimento de radiomarcação foram testadas diferentes fases 
móveis e fases estacionárias. Para optimizar a radiomarcação do BSA foram testados 
diferentes parâmetros, nomeadamente, a concentração de ligando e agente redutor, pH, a 
actividade do radionuclídeo, temperatura e tempo de incubação. Para avaliar a 
biodistribuição dos radiofármacos foi realizado um estudo comparativo entre o 99mTc-BSA e 
o 99mTc-BSA-NP. Ambos os complexos foram administrados por gavagem a ratinhos Balb/c. 
Os animais foram sacrificados a diferentes intervalos de tempo: 0, 30, 60, 90, 120, 180, 360 e 
1440 minutos após a administração. O tracto gastrointestinal e vários órgãos e fluidos foram 
recolhidos, para além disso, o conteúdo gastrointestinal foi separado da parede 
gastrointestinal, que por sua vez foi lavada. Todo o material biológico recolhido foi pesado e 
a radioactividade foi avaliada pelo processamento das imagens e foi calculada a percentagem 
de actividade administrada por miligrama. 
A pureza radioquímica foi determinada com recurso a dois sistemas cromatográficos, 
cuja fase estacionária eram tiras de cromatografia em camada fina instantânea-gel de sílica 
(do inglês, ITLC-SG) e a fase móvel era NaCl (cloreto de sódio) e ACD (ácido de citrato-
dextrose). A pureza radioquímica obtida foi superior a 95% e mantem-se estável por 6h. 
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Estes resultados foram obtidos com 10mg.ml-1 de tiossulfato de sódio; HCl (ácido clorídrico), 
N; 10mg.ml-1 de BSA; tampão fosfato a pH 7.4, (1.0/1.0/2.5/2.0) (v/v/v/v) e 1110 to 2220 MBq 
de Na99mTcO4
- (pertecnetato de sódio). Os estudos de biodistribuição revelaram que o 
99mTc-BSA-NP tem um perfil diferente de adesão à parede do estomago e do intestino 
delgado, independente do perfil de progressão do conteúdo ao longo do tracto 
gastrointestinal, quando comparado com a biodistribuição do 99mTc-BSA. Seis horas após a 
administração dos radiofármacos estes encontram-se maioritariamente no intestino grosso e 
24h após a administração toda a actividade já foi eliminada.   
O procedimento de marcação do BSA é estável e reprodutível e revela potencial 
para acompanhar o BSA. As diferenças entre o 99mTc-BSA-NP e o 99mTc-BSA parecem ser 
devidas às propriedades mucoadesivas dos polímeros que constituem as nanoparticulas, mais 
concretamente o quitosano. Contudo, para avaliar a absorção da insulina devem ser 
efectuados outros estudos.  
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1.1 Diabetes mellitus 
Diabetes mellitus is a descriptive term for a family of disorders that are characterized by 
chronic carbohydrate intolerance and the development of long-term medical complications. 
Under normal circumstances, the body must maintain blood glucose concentrations ranging 
60-109 mg/dL (3.3-6.1 mmol/L) during fasting to avoid hypoglycemia and hyperglycemia. 
When hyperglycemia is persistent, diabetes mellitus is diagnosed (KNOWLER, 2005). The 
number of diabetic patients has been sharply increasing around the world, assuming an 
epidemic dimension. It is predicted that in 2030 366.2 million of people will have diabetes 
mellitus (WILD, et. al., 2004).  
Blood glucose concentrations are controlled primarily by hormones that regulate the 
rates of glucose consumption. The primary hormonal regulators of glucose production and 
consumption are insulin and glucagon, both produced by pancreas. Insulin release is 
stimulated by the increasing of blood glucose and also by the increasing of amino acid 
concentration after meals. In order to act on target tissues, insulin must bind to the insulin 
receptor, present on many types of cells, although the major sites of its location are the 
liver, muscle and adipose tissue. The balance between insulin secretion and glucagon 
secretion maintains the blood glucose concentration within strict limits. When insulin 
concentrations fall, glucagon concentrations rise, accounting for hyperglucagonemia, which is 
characteristic of diabetic states (KNOWLER, 2005). 
Generally, diabetes mellitus is characterized by high blood glucose levels and the chronic 
states of disease have several complications, such as diabetic retinopathy with vision loss, 
nephropathy, peripheral neuropathy, and other several dysfunctions such as at gastric, 
intestinal, genito-urinary and sexual level. Furthermore, diabetes increases the prevalence of 
cardiovascular atherosclerosis, peripheral vascular and cerebrovascular disease (GEISS, 2000; 
KNOWLER, 2005). 
There are different types of diabetes, such as type I, type II, gestational and other types. 
Type I diabetes is characterized by pancreatic β cell destruction leading to absolute insulin 
deficiency, and it can be immune-mediated or idiopathic. Generally it begins in the childhood 
or in the adolescence, although it can occur in any age and represents 5% to 10% of the 
cases of diabetes. This diabetic type is characterized by total absence of insulin production 
and for this reason the need of insulin therapy is imperative (GEISS, 2000).  
Type II diabetes is the most common, representing 90% of the diabetic patients and it is 
characterized by metabolic states that range from predominantly insulin resistance with 
relative insulin deficiency to a predominantly secretory defect with insulin resistance without 
a relation to autoimmune mechanisms. In these cases the origin of disease is related to 
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environmental and genetic factors. The therapy includes antidiabetic drugs and the insulin 
therapy is just an alternative that represents 35% of the patients with type II (GEISS, 2000).   
Gestational diabetes mellitus is diagnosed when hyperglycemia of any degree is first 
recognized during pregnancy. Thus, there is possibility that diabetes occurs before the 
pregnancy but remained unrecognized until its medical visits. The definition applies 
regardless the method used to control glycemia, diet or insulin, during pregnancy and even 
this disorder persists postnatal (GEISS, 2000).  
Normally the other type appears due to genetic defects related to pancreatic β cells 
function, insulin action or exocrine pancreas function (e.g. pancreatitis, pancreatectomy, 
tumors, cystic fibrosis). It can also be related to endocrinopathy (e.g. acromegaly, glaucoma, 
pheochromocytoma, hyperthyroidism, somatostatinoma). Furthermore, diabetes can be 
induced by drugs (e.g. streptozotocin, alloxan and the rodenticide Vacor are likely to cause 
permanent diabetes) and infections (GEISS, 2000; GITTOES, et. al., 2010).  
1.1.1 Insulin 
Insulin is an anabolic protein produced by the β cells of pancreatic islets of Langerhans, 
generated prions from insulin precursor composed by three polypeptide chains, A, B and C. 
The proinsulin precursor is cleaved and stored in Golgi secretory vesicles, where scission of 
C chain occurs and the final form of insulin is obtained (figure 1). The A chain has two α-
helix (A1-A8 and A13-A21) linked to each other in an antiparallel way, while the B chain has a 
central α-helix (B9-B19), flanked by extended amino- and carboxyl-terminal strands. Some 
residues of the A chain form an apolar nucleus, being insulin surface composed by both polar 
and apolar residues. Thus, the hormone has a compact three-dimensional structure, 
consisting on three helices and three conserved disulfide bridges (figure 1). This structure is 
determined by disulfide bridges position and Van der Waals strength which are essential for 
insulin activity (CHIEN, 1996).  
 
 
 
 
 
 
 
 
Figure 2 – Insulin structure. InsA represents A chain of insulin, InsB represent B chain of insulin and the disulfide 
bridges are represent in green. Extracted from MENTING 2012. 
Figure 1 – Insulin structure. InsA represents A chain of insulin, InsB represent B chain of insulin and the 
disulfide bridges are represent in green. Extracted from MENTING 2012. 
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Insulin structure is sensible to high temperatures, high humidity, organic solvents, 
mechanical agitation, ultrasounds, and water-solvent and water-air interfaces. These factors 
can lead to molecular degradation, denaturation or insulin aggregation (BRANGE, 1987).  
In physiological conditions the insulin concentration is lower than 10-3µM to ensure its 
biological activity. In higher concentration, insulin has tendency to dimerize and lose the 
monomeric form that is responsible for the hypoglycemic activity of insulin. Insulin molecule 
has fifty-one amino acids, six of them with positive charge and ten with negative charge. The 
isoelectric point of insulin is between 5.3 and 5.4 (BRANGE, 1987).  
Insulin pharmacodynamics is complex and it is dependent of several factors, such as its 
administration pathway, hepatic function and glucose concentration. As previously 
mentioned, insulin regulates glucose metabolism, but it also is involved in lipogenesis, in 
decreasing of lipolysis and ketone production. Furthermore, insulin promotes DNA 
synthesis, cell’s replication, and interacts with insulin-like growing factors and relaxins, 
influencing modulation of transcription and RNAm cell contents (CHIEN, 1996). In some 
tissues like muscles, insulin promotes glucose and amino acids uptake. In the liver, insulin 
stimulates glucose storage in the glycogen form, decreasing gluconeogenesis and increasing 
triglycerides production from glucose (CHIEN, 1996).  
Liver and kidney are the principal pathways to insulin clearance. The first-pass extraction 
in the liver rounds 70% while the kidney metabolism degrades 10-40% of insulin per day. 
Insulin degradation occurs by catalysis of the reducing links of disulfide bridges by the insulin 
enzyme, insulinase. These reduced chains are then hydrolyzed in smaller fragments, which 
can occur in the liver, pancreas, muscle and adipose tissues (CHIEN, 1996).  
1.1.2 Insulin therapy 
The conventional insulin therapy consists in its subcutaneous administration being its 
bioavailability between 55 and 77% (GEISS, 2000). The most frequent complication of insulin 
therapy is hypoglycemia, besides the fact that when insulin is injected subcutaneously, it is 
exposed to all tissues in the same concentration and just a fraction of the injected dose is 
provided to the liver. Muscles and adipocytes can thus respond to the injected dose without 
hepatic processing of the insulin supply. Therefore, the excessive exposure of the vascular 
system and other smooth muscles to injected insulin may trigger its damaging 
overstimulation of growth, cell division and other metabolic responses that form the 
continuum of diabetic complications (REIS, et. al., 2006; GEISS, 2000).  
Newer methods of insulin delivery have been developed, including insulin pen systems, 
aerosol injectors, insulin inhalers, infusion pumps and jet injectors (AL-TABAKHA 2008). 
Introduction 
6 
 
Insulin pen systems (figure 2A) eliminate the inconvenience of carrying separately insulin, 
syringes and needles, moreover they are quick and easy to use, discreet, durable, flexible and 
do not need refrigeration. To use this device, the diabetics must attach a needle, prime the 
pen, set the dose by a dial and depress the plunger to administer subcutaneously the 
selected dose (AL-TABAKHA, 2008; SELAM, 2010). The insulin pump (figure 2B) permits a 
continuous subcutaneous insulin infusion that can be adjusted to the specific need of the 
patient in order to maintain the basal levels of insulin and glucose in the blood throughout 
the day. The pump device allows that the patient have an overall quality of life, however, if 
the insulin delivery is interrupted by infusion set malfunction, needle displacement or lack of 
insulin in the reservoir, circulating insulin concentration decrease suddenly and a 
hyperglycemic episode can occur (SELAM, 2010; SUBHASHINI, 2013). 
 
 
 
Aerosol injectors (figure 3) deliver insulin in the mouth and they are still under 
development by the biotechnology industry. As well as the insulin inhalers, those are under 
consideration to insulin delivery due to large surface area of lungs (SELAM, 2010; 
SUBHASHINI, 2013). 
 
  
Figure 2 – Insulin delivery devices. A-Insulin pen system. Adapted from Diabetes Guide Today, 2014. B- 
Insulin pump. Adapted from Medtronic MiniMed Paradigm Insulin Pumps Lawsuit, 2014 
Figure 3 -  Aerosol insulin injector. Extracted from How to give an insulin injection, 2014 
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Jet injectors (figure 4) are developed to deliver insulin in a transcutaneous level at high 
speed and pressure to penetrate the skin without a needle. The insulin injected by this 
method is quickly absorbed but the repeated use of jet injectors potentiates a decrease of 
insulin absorption. Additionally, the use of this device is painful and its size and cost makes it 
unfavorably and often limits the routine use by patients (SELAM, 2010; SUBHASHINI, 2013). 
 
 
 
Alternatively, the oral insulin administration could be ideal to the treatment of diabetes 
mellitus and even it does not replace the parenteral administration it will be certainly a 
complementary approach. The benefits of oral administration are many and have a wide 
range. In addition to patient adherence to the treatment be easier because oral 
administration is noninvasive, relatively free from complications and easily dosed, the 
exogenous insulin absorbed in the intestine can mimic much better the endogenous insulin, 
since in the bloodstream the insulin goes to the liver where it has a fundamental function 
(GORDON, 2002; CERNEA, 2006). 
Considerations associated with developing effective oral formulations for proteins and 
peptides are generally attributed to their susceptibility to be degraded by luminal secretions, 
to their interaction with luminal membranes and to its contact with cytosolic enzymes 
before they can reach the bloodstream. Another concern is the metabolic activity of 
microflora in the lower small and large intestines, because bacterial colonies are capable of 
several metabolic reactions, such as deglucuronidation, decarboxylation, ester and amide 
hydrolysis, and dehydroxylation. Moreover, the poor intrinsic permeability of peptides and 
proteins to cross biological membranes as a result of their large molecular size, charge and 
protein hydrophilicity, limits their uptake through aqueous pores in the gut wall (GEISS, 
2000; REIS, et. al., 2006).  
The oral administration of insulin has been largely studied. Based on these 
considerations, many possibilities have been considered, namely, (1) enzyme inhibitors in 
microparticles or nanoparticles (NP), whose usage has been questioned because of the long 
term toxicity (DAMGÉ, et. al., 1997; QI, 2004; PEPPAS, 2006); (2) absorption promoters in 
capsules of gelatin, however the promoters’ toxicity is not consensual and the disadvantage 
Figure 4 - Insulin jet injector. Extracted from Pharmjet introduces needle-free subcutaneous and intramuscular 
injectors, 2014 
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is the nonspecific effect (TOUITOU, 1986; HOSNY, 1995); (3) use of liposomes, which, 
although its effectiveness has been proven in many fields of pharmaceutical technology, the 
results are strongly contradictory mainly due to its composition (SIMÕES, 2005); (4) use of 
NP, whose results are promising since its first approach by Oppenheim et. al. (1982).  
NP are under consideration for oral delivery of proteins like insulin by stabilizing and 
ensuring biological activity during transit through the gastrointestinal tract and by facilitating 
delivery and absorption in the target site. Insulin absorption from the gastrointestinal tract 
into the portal vein would mimic the physiological route of insulin undergoing first hepatic 
bypass. Compared to parenteral delivery, less insulin would be necessary to obtain a 
therapeutic effect and, consequently, secondary effects due to high insulinaemia in 
extrahepatic tissues would be minimized. Besides this, NP prolong the permanence time of 
insulin in the intestine, which promotes high dispersion at the molecular level and 
consequently increases absorption (REIS, et. al., 2006; WOITISKI, et. al., 2009b).  
1.2 Nanoparticles 
NP as drug carriers are composed by natural, semisynthetic, or synthetic polymeric 
molecules of nanometer size which may or may not be biodegradable. NP are a collective 
name for nanospheres and nanocapsules. Nanospheres have a matrix-type structure; drugs 
or tracers may be absorbed at their surface, or entrapped or dissolved within the particle. 
Nanocapsules are vesicular systems in which the drugs are confined to a cavity or inner 
liquid core surrounded by a polymeric membrane (REIS, et. al., 2006).  
The size of NP is a main player regards its high intracellular uptake but also by its 
influence in intestinal absorption. The critical diameter to intestinal absorption of NP is 
10µm as maximum limit; this factor is the most preponderant and it influences the 
biodistribution, the release profile and the mucoadhesive properties (GOMBOTZ, 1998; 
JUNG, 2000). Polymeric composition (hydrophobicity, surface electric charge and 
biodegradation profile), nature of adjuvants and drugs (molecular weight, charge and 
localization on nanoparticle) have high influence in NP absorption, distribution, metabolism 
and elimination. Thus, the design of NP involves interconnected processes toward 
developing and optimizing NP formulation, based on physicochemical, pharmacological and 
physiological parameters. Considering that, the design of NP for orally dosed insulin is a 
promising approach for the treatment of diabetes mellitus, attempts include the use of 
biomaterials that have demonstrated favorable characteristics for protein entrapment, 
absorption across the intestinal membrane and delivery to the target site (JUNG, 2000; REIS, 
et. al., 2006; WOITISKI, et. al., 2009b).  
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Many have been the approaches used in the development of NP for oral delivery of 
insulin. There are many compounds available to use in NP formulation, such as 
polyisobutylcyanoacrylate (PIBCA), poly(alkylcyanoacrylate) (PACA), 
poly(methylmethacrylate) (PMMA), polylactic acid (PLA), poly(lactic-co-glycolic acid) (PLGA) 
and others, which results have showed hypoglycemic effect in diabetic mice (HANEMANN, 
2012; JAWAHAR, 2013). Nowadays, the feed lines in nanotechnology are directed to the 
use of natural polymers. Actually, polymers derived from natural and renewable sources are 
increasingly interesting to pharmaceutical industry due to its biocompatibility, 
biodegradability, gelation possibility, and easy, quick and accessible acquisition. There are 
several polymers with these characteristics, like agar, agarose, carrageenan and alginate. 
Among these polymers, alginate is the most advantageous and has become increasingly 
important in many areas. A higher number of studies have been carried out with this 
polymer; however, the optimization of the formulation that are related with the size of the 
particles obtained, the efficiency of encapsulation, the bioavailability and the hypoglycemic 
effect achieved in vivo studies are the major difficulties to overcome (ONAL, 2002; CUI, 
2004; SILVA 2006).  
1.2.1 Alginate 
Pharmaceutical industry has used a matrix-alginate to encapsulate several drugs. This 
choice is related to alginate ability to form a gel in the presence of multivalent cations with 
compatible conditions with encapsulated drugs. Another advantage of alginate is that it 
undergoes partial degradation in human gastrointestinal tract which makes it similar to 
soluble dietary fiber, and it is also free of toxicity and immunogenicity (GOMBOTZ, 1998; 
BURTING, 2003; WOITISKI, et. al., 2009b). In addition, alginate has bioadhesive properties 
due to a high quantity of carboxyl groups that establish hydrogen bonds with mucus 
intestinal glycoproteins, which is an advantage to delivery drugs in the intestine. Besides, the 
sensibility of alginate to pH changes allows the release of encapsulated drugs (WOITISKI, et. 
al., 2009b). 
Alginate is a natural polymer extracted from brown algae (Phaeophyceae), being one of 
the most available polymers, and to commercial purpose Macrocystis pyrifera, Laminaria 
hyperborean and Ascophyllum nodosum are the most used species to extract alginate 
(Gombotz 1998). Alginate consists of a polysaccharide of anionic chains not branched with 
two types of polyuronic acid, the β-D-mannuronic acid (M) and α-L-guluronic (G) acid linked 
by (1,4) glycosidic bonds. These monomeric units can naturally appear in three different 
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combinations (figure 5), heteropolymeric units (MGM) or monomeric units (GGG or MMM) 
(LIU, 2002a; WOITISKI, et. al., 2009b). 
 
 
 
 
 
 
 
 
Alginate has gelling properties that allows the formation of two kinds of gel, an acid gel 
and an ionotropic gel. The ionotropic gel is formed in the presence of some divalent and 
trivalent cations and can retain in the core, drugs or other compounds.  
The alginate composition should be considered in the gelling phase because it has a big 
influence in intumescence and its availability to encapsulate drugs. During the gelling, cations 
binds preferentially to guluronic residues, thus the content of these residues affects the 
hardness, the porosity, the stability and the elasticity of gel, and the size and shape of the 
particles formed (GOMBOTZ, 1998; PONCELET, 2001; SARMENTO, et. al., 2007a).  
Alginate is a hydrophilic polymer with slow dissolution in cold water, but once dissolved 
originates viscous colloidal solutions. The solubility of alginate in aqueous solution is 
determined by the cations and other compounds present in the solution, temperature and 
pH changes. Concerning pH, when pH is higher than its pKa, alginate is negatively charged 
and its hydration occurs. On the other hand, when pH is lower than the pKa of alginate (3.38 
and 3.65 to mannuronic and guluronic residues, respectively) it precipitates in the form of 
alginic acid (SHILPA, 2003). 
Sodium alginate used in nanoencapsulation techniques should have a concentration 
between 1-3% (m/v). If alginate’s concentration is lower than 1% (m/v) the carboxylic groups 
are insufficient to form spherical particles during the gelling (SARMENTO, et. al., 2007a). If 
the concentration of alginates is above 3% (m/v), viscosity increases and consequently the 
size of the obtained particles increase as well (LIU, 2002a).  
Basically, alginate forms a stable and reversible hydrogel in the presence of multivalent 
cations due to intramolecular and intermolecular cross-linking, resulting in compact coiled 
chains of a pre-gel state. Calcium is a cation widely used in the gelling process of alginate, 
because it is safe to clinical applications, easily available and cheap. However, other divalent 
cations, such as Sr2+ (strontium) and Ba2+ (barium) and trivalent cations, such as Fe3+ (iron) 
Figure 3 – Alginate structure, G and M residues. Extracted from Liu 2002a.  
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and Al3+ (aluminum) can also be used, but monovalent cations and Mg2+ (magnesium) are not 
able to form alginate gel (RAJAONARIVONY, 1993; GOMBOTZ, 1998; WOITISKI, et. al., 
2009a).  
In the mechanism of gelling alginate the interactions occur preferentially between 
calcium ions and guluronic units making a strong and thermostable gel, whose properties 
depend on the polymer characteristics and the NP preparation method. Calcium bonds to 
alginate by electrostatic interactions but also by bonding to 7-9 atoms of oxygen to carboxyl 
and hydroxyl groups of four different monomers. Furthermore, each alginate chain can 
dimerize to form junction zones trough bonds between polysaccharide chains making a solid 
gel and this is possible due to calcium quelation (GOMBOTZ, 1998; SHILPA, 2003). A few 
salts of calcium can be used, such as oxalate, tartrate, phosphate, carbonate and citrate. 
Among these salts, carbonate of calcium shows the best results because obtained NP are 
spherical, have unimodal size distribution, stable, and remain stable in a wide pH range 
(PONCELET, 2001). The grain size of calcium salt has a big influence on NP aspect, size and 
resistance. As lowest the size of the grain calcium salt is, the bigger will be the calcium ion 
quantity widespread between the chains of alginate and the gel will be much more stable 
(PONCELET, 2001).  
1.3 Insulin-NP 
NP studied in this work were formulated by emulsification/internal gelation. They were 
described as a multilayer complex with the insulin protected and retained within the 
nanoparticle which had an outermost coat consisting of a protease-protective protein. The 
nucleus’ particle consists of calcium cross-linked alginate, dextran sulfate and insulin 
following complexation with chitosan and outermost coated with bovine serum albumin. The 
figure 6 shows a schematic representation of this NP. (WOITISKI, et. al., 2009a; WOITISKI, 
et. al., 2009b).  
 
 
 
 
 
 
 
 
 
Figure 6 – Schematic representation of multilayered NP encapsulating insulin. NP are formulated by calcium 
cross-linked alginate, dextran sulfate and insulin following complexation with chitosan and outermost 
coated with bovine serum albumin. Adapted from WOITISKI 2010. 
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The production method of polymeric network designated internal gelation was 
developed with alginate as base polymer. It consists of a mixture of sodium alginate and a 
calcium complex, and, by decreasing pH, the calcium ion is released from the complex and 
reacts with alginate. This method was adapted to produce particles in gel, to turn over the 
toxic products resulting, and currently is designed by emulsification/internal gelation (LIU, 
2002a). 
1.3.1 Emulsification/internal gelation  
The emulsification/internal gelation method involves the preparation of an insoluble salt 
calcium suspension in an alginate solution. This mixture is scattered in oil, in the presence or 
absence of emulsifier agent, and the result is a W/O (water in oil) emulsion. After this, the 
calcium salt is dissolved by the addition of an acid and the alginate gelation occurs by 
reticulation with calcium ions. The oil used in emulsification/internal gelation method can be 
obtained from nature (e.g. corn, peanut and soybean) or minerals (e.g. paraffin oil, isooctane 
oil and silicon). The ratio of aqueous phase and oil phase has influence in the size of the 
particles formed, and it is typically between 1:1 and 1:5 (v/v) (LIU, 2002a). 
The emulsifier agent has two functions in the emulsification process, the decrease of the 
surface tension facilitating the dispersion of aqueous and oil phases and the surface 
stabilization avoiding the coalescence of the droplets. One of the most important aspects of 
the emulsifier agent is the ability to quickly form a film around of each droplet of internal 
phase, avoiding its coalescence when they come into contact with each other’. In 
emulsification/internal gelation process several emulsifier agents have been tested, such as, 
lecithin, sorbitan monooleate (Span® 80), sorbitan trioleate (Span® 85) and, polyoxyethylene 
sorbitan monooleate (Tween® 80) (LIU, 2002a; LIU, 2002b).  
The emulsifier agent concentration is a very important factor in the 
emulsification/internal gelation method. When it is too low (<0.5%, v/v) the film formed 
around the droplets can be incomplete decreasing droplets stabilization. On the other hand, 
concentrations higher than 2.0% (v/v) can cause resistance to pH reduction, increasing the 
gelation time that decreases the process income (LIU, 2002b). When one acid is added to 
the oil and it scatters in the aqueous phase, pH decreases immediately, and then the calcium 
complex solubilizes and the cations are available to alginate gelation. The acid concentration 
should be studied and controlled to obtain the desire effect without damaging the agent to 
encapsulate. There are a few acids soluble in oil suitable to emulsification/internal gelation 
process, such as, acetic acid, citric acid and lactic acid (LENCKI, 1989).  
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To sum up, the emulsification/internal gelation method is safe, simple and economic. The 
low stress of the process allows the use of very sensible agents. Furthermore, a 
homogeneous gel is obtained and the size of the particles can be controlled. On the other 
side, the porosity of particles obtained can be a limiting factor, because it can decrease the 
entrapment efficiency and increase the velocity of release of encapsulated agent in 
gastrointestinal fluid. All these factors should be considered in the design of NP obtained by 
this technique (PONCELET, 1992; VANDENBERG, 2001).  
Transposition of this method for industrial scale could be easy because it is possible to 
produce a large number of particles without highly sophisticated equipment. Poncelet et al. 
(1992) studied the equipment influence in NP size and in the batch yield, regarding two 
factors, the reactor geometry and the impellers type. Thus, a round bottom reactor 
increases the income of the batch because it avoids the appearance of dead volumes during 
agitation and, consequently, alginate solution accumulates and forms aggregates. In respect to 
impellers type, the marine impeller showed the best results when compared with the 
impeler network, due to lower adhesion and aggregation performed. Furthermore, the 
marine propeller allows a higher homogeneity when compared with six turbine blades.  
The recuperation of the NP scattered in the W/O emulsion should be performed with 
appropriate wash. Usually this is achieved adding an aqueous washing medium that perturbs 
the W/O emulsion equilibrium causing the phases inversion. It allows the migration of the 
NP from the oil phase to aqueous phase. The recuperation factors should be strictly 
controlled because there is a risk to form very stable O/W (oil in water) emulsion 
precluding the recuperation of NP (ARSHADY, 1990; PONCELET, 1992). There are several 
aspects to consider in the recuperation process, such as, NP size and shape, oil elimination 
easiness, number of wash cycles, recuperation income, entrapment efficiency, insulin release 
profile and physic-chemical stability of encapsulated insulin (PONCELET, 1992).  
1.3.2 Reinforce the alginate matrix 
Considering nanoencapsulation, the entrapment efficiency is very important and at this 
point the emulsification/internal gelation method has a disadvantage due to insulin release in 
acidic medium. As mentioned above, NP should have ability not only to encapsulate insulin 
but also to release the encapsulated agent, only in target site. Thus, a way to control the 
release profile is to add other polymers to alginate matrix. The polymers to reinforce 
alginate matrix must have negative charge because it is the same charge of alginate, so the 
formation of complexes between these two polymers is almost unlikely. If alginate interacts 
with a second polymer and it forms a complex, the insulin entrapment will be conditioned. 
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On the other side, adding an anionic polymer could increase the insulin entrapment on 
alginate matrix because the matrix stays denser and the insulin diffusion becomes difficult. 
Besides, insulin-anionic polymer interaction forms a polyelectrolyte complex that is 
reversible which is an advantage to release insulin in its native conformation (CHAN, 1997).  
Additional incorporation of dextran sulfate improves insulin entrapment efficiency and it 
modulates insulin release from NP (WOITISKI, et. al., 2009a). Dextran sulfate is a branched 
chain polymer with biodegradable and biocompatible properties. It has low molecular weight 
(5kDa) and it is a strong anionic polymer that contains 2.3 sulfate groups per glycosyl 
residue. Sulfate dextran interacts with isolated ions, like calcium, and polycationic polymers. 
This polymer has high purity and stability and it is very useful to selectively precipitate 
lipoproteins, to hybridization reactions, and to protein stabilization reactions. As hydrophilic 
polymer can contribute to water-soluble proteins encapsulation, and it can also promotes 
longer periods of circulation in vivo (REIS, 2008; WOITISKI, et. al., 2009a; WOITISKI, et. al., 
2009b).  
1.3.3 Insulin-NP coating  
Alginate and chitosan NP have been widely used and extensively reported for oral 
delivery of insulin. Chitosan is positively charged and consequently it is used for the 
incorporation of other polyanionic polymers to modulate insulin entrapment, stability, 
retention and release in the gastrointestinal tract (WOITISKI, et. al., 2009a; WOITISKI, et. 
al., 2009b).   
Chitosan is an unbranched polyamine of D-glucosamine and N-acetyl glucosamine with 
mucoadhesive, biodegradable and biocompatible properties and it can be derived by partial 
deacetylation of chitin from crustacean shells. It has potential to reduce transepithelial 
electrical resistance and transiently opens tight junction between epithelial cells to enhance 
insulin absorption via paracellular pathway (WOITISKI, et. al., 2009a; WOITISKI, et. al., 
2009b). Chitosan is important to stabilize the alginate hydrogels in the formation of NP, 
reinforcing the fragile alginate nucleus, due to its pH-sensitive behavior. It is soluble at low 
pH due to protonation of amino groups and insoluble at higher pH values. The acid type 
used to dissolve chitosan influences the stability, strength, mucoadhesive and disintegrating 
properties determining the physicochemical properties of NP. Lactic acid is normally used to 
dissolve chitosan and provides greater bioadhesive and flexible elastic properties than 
chitosan dissolved in acetic acid (WOITISKI, et. al., 2009a; WOITISKI, et. al., 2009b). 
Stabilizers are important to modulate the structural properties of NP with high 
tendency to aggregate by providing stability in suspension and influencing interaction 
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between particles and enzymes, and cells and its membranes. Steric stabilization of NP is 
induced by poloxamer 188 that is a nonionic triblock copolymer composed of a central 
hydrophobic chain of polypropylene oxide and two hydrophilic chains of polyethylene oxide. 
Poloxamer is bound to the nanoparticle surface by hydrophobic interaction of the 
polyethylene oxide chains with methyl groups of chitosan, while the hydrophilic polyethylene 
oxide chains protrude into the surrounding medium to create a steric barrier. Poloxamer 
reduces particle aggregation and enzyme adsorption in gastrointestinal tract, which may 
interfere with the nanoparticle carrier function by degrading insulin (WOITISKI, et. al., 
2009b).  
Additionally, improvement of insulin protection against enzymatic degradation 
represents an essential strategy in the successful oral administration of insulin-based NP. 
Factors that counteracted the pharmacological effect of orally dosed insulin were calculated 
as 60% due to insulin degradation, 23% due to premature insulin release and 17% due to lack 
of mucoadhesion. By these factors, albumin coating is designed to minimize acid degradation 
and to prevent proteases from accessing insulin within the nanoparticle, acting as a sacrificial 
target to enzymatic degradation (WOITISKI, et. al., 2009b).  
1.3.3.1 Albumin  
The albumin has widely been studied and has several applications at pharmaceutical 
industry. Considering the nanotechnology, the albumin has been used in three different ways, 
as drugs model to be encapsulated, as main polymer to encapsulate other drugs and, as 
coating polymer at polymeric NP. In this work, as previously mentioned BSA is used to coat 
NP. This choice is based in other works that showed an increase in the stability of 
alginate-NP and has a protecting effect on insulin (HURTEAUX, 2005; SCHECHTER, 2005).  
Serum albumins are the most abundant soluble circulatory proteins in the blood 
(52-60% of plasma) of mammalians and they are exclusively synthesized by the parenchymal 
cells of the liver. The half-lives are variable and the bovine serum albumin has a half-life of 19 
days. Serum albumin is crucial to maintaining plasma volume and the osmotic pressure of 
circulating blood. In addition, it also has function as carrier for hormones, enzymes, fatty 
acids, bilirubin, metal ions, and medicinal products to the target tissues. The albumin helps in 
the metabolism and affects the pharmacokinetics of many drugs, reduces the activity of 
toxins, acts as free-radical scavenger and sometimes displays pseudo-enzymatic properties 
(WANG, et. al., 2007; WANG, et. al., 2011).  
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Human serum albumin (HSA) is a globular protein with a single polypeptidic chain, 
consisting of 585 amino acid residues. It contains low quantities of tryptophan and high 
cysteine’s quantities and its secondary structure consists in α-helix having six turns and 
seventeen disulphide bridges. Bovine serum albumin (BSA) shares approximately 76% 
sequence homology with HSA (figure 7), which is also a single polypeptidic chain with 583 
amino acid residues. BSA has seventeen disulphide bridges, as well, and one free -SH group, 
which makes possible the formation of a covalently linked dimer. These proteins are charged 
amino acid residues with apolar surface, and their interior is almost hydrophobic, in nature. 
Besides, BSA is characterized by three domains, each consisting of a large and a small double 
loop and a short and a long connecting segment. The major difference between HSA and 
BSA is that the first is human and contains only one tryptophan amino acid residue while the 
latter is bovine and has two residues. BSA has an isoelectric point of 4.7 while HSA has the 
isoelectric point of 5 (URBANO, 2004; AKDOGAN, 2012). 
 
Usually, the plasmatic proteins are not internalized by the cells, which use plasmatic 
amino acids to produce their proteins. Thus, albumin and the other plasmatic proteins 
perform its functions in the plasma or interstitial fluid. Once synthesized, albumin molecules 
are secreted into the blood stream and extravasate from the intravascular space to the 
interstitial space. Apparently, albumin breakdown occurs directly from the intravascular 
compartment, probably by the endothelial cells. The kidney degradates about 10% of albumin 
and more than 10% seems to be leaking into the gastrointestinal tract. Albumin present in 
the interstitial space returns by the lymphatic flow back to the intravascular compartment 
(URBANO, 2004). 
1.4 Insulin-NP characterization  
To optimize formulation of NP several parameters should be taken in account, such as 
their size distribution, polydispersity index, zeta potential, insulin entrapment efficiency, 
insulin release in gastric and intestinal simulation conditions and in vivo pharmacological 
activity (SARMENTO, et. al., 2007b; WOITISKI, et. al., 2009b).  
Figure 7 –Crystal structure aligment of HSA (blue) and BSA (red). Adapted from Akdogan 2012. 
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1.4.1 NP size 
NP average diameter is dependent upon NP composition, mainly the concentration of 
calcium chloride, chitosan, and albumin. Calcium concentration affects significantly the NP 
size and, intramolecular cross-linking of individual alginate chains ledding to a pregel state 
and compact coiled structure, but an increase calcium concentration results in gel 
aggregation and consequently the formation of bigger particles. Chitosan complexation 
contributes to the alginate nucleus size in proportion to its initial diameter, since larger 
nuclei have more carboxylic groups to interact with amino groups of chitosan. The albumin 
concentration effect on decreasing nanoparticle diameter, possibly related to a reduction in 
the electrical repulsion among biopolymers, where modifications in the electrical state cause 
swelling or shrinking of the particle, depending on whether the electrical repulsions increase 
or decrease, respectively (WOITISKI, et. al., 2009a; WOITISKI, et. al., 2009b).  
Polydispersity index represents the size distribution, and the mean value decreases 
when calcium chloride concentration is low, however it does not depend on chitosan or 
albumin concentrations. Calcium reduces nanoparticle aggregation that results in a narrower 
but polydisperse particle size distribution (WOITISKI, et. al., 2009b).  
1.4.2 Zeta potential 
Zeta potential lower than -30mV which shows higher electrostatic stabilization of NP in 
suspension, whereas large repulsive forces prevent aggregation upon random impact of 
adjacent NP. It is an important parameter for insulin physicochemical and biological stability. 
The negative zeta potential shows the prevalence of negative charges suggesting the 
presence of albumin on the nanoparticle surface that interacts with positively charged 
chitosan at a pH above the albumin isoelectric point (WOITISKI, et. al., 2009a; WOITISKI, et. 
al., 2009b).  
1.4.3 Entrapment efficiency 
Entrapment efficiency of insulin it is influenced by many factors. High insulin entrapment 
values were obtained with high concentrations of calcium chloride (0.24%), which can be 
explained by ionic bridges established between carboxylic residues of insulin amino acids and 
alginate chains when calcium ions interact with guluronic residues of alginate, and 
consequently the insulin association to alginate nucleus is enhanced (WOITISKI, et. al., 
2009b). Entrapment efficiency is higher to lower albumin concentrations (0.25% and 0.50%), 
because the addition of albumin solution at pH 5.1 raises the pH of the nanoparticle 
suspension to the isoelectric point of insulin, decreasing the electrostatic interaction 
strength between insulin and alginate/dextran sulfate nucleus. The lowest entrapment 
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efficiency is obtained with a low calcium chloride concentration and a high albumin 
concentration (WOITISKI, et. al., 2009b). 
1.4.4 Release profile in vitro  
Insulin release in enzyme-free simulated digestive fluids was carried out to define insulin 
retention within NP and its ability to prevent insulin from acid degradation. Insulin release is 
influenced by NP’ swelling based on chitosan properties at low pH that facilitates the 
diffusion of ions present in the simulated gastric fluid inside them, breaking the ionic 
interaction between insulin and nanoparticle nucleus. Thus, high concentration of chitosan 
increases insulin retention, as well as high concentration of albumin results in higher insulin 
release, likely due to a weakening of electrostatic interaction between insulin and the 
alginate/dextran nuclei, which is reliant to pH conditions (WOITISKI, et. al., 2009a; 
WOITISKI, et. al., 2009b).  
Ideally, insulin remains associated with NP in gastric conditions, and it is only released at 
the intestinal pH where the absorption potential is optimal. After gastric simulation, NP 
were transferred to enzyme-free simulated intestinal fluid and high levels of cumulative 
insulin release take place after 180 minutes in the simulated intestinal fluid (SARMENTO, 
2007a). Thus, it appears that pH triggers insulin release, potentially as NP pass from the 
acidic gastric medium, into a neutral intestinal medium, which can be attributed to 
electrostatic repulsion between alginate and insulin, both staying negatively charged. 
Moreover, dissolution of the alginate nucleus, as a result of calcium loss and alginate swelling, 
can happen. This combined with the mucoadhesive properties of alginate and chitosan, which 
stay exposed after degradation of the sacrificial-target albumin in the stomach, would result 
in adhesion of the NP to the intestinal mucosa to release insulin directly at the site of 
absorption (SARMENTO, et. al., 2007a; SARMENTO, et. al., 2007b; WOITISKI, et. al., 2009a; 
WOITISKI, et. al., 2009b).  
1.4.5 In vivo characterization 
The pharmacological effect of insulin-NP was evaluated in a work (SARMENTO, et. al., 
2007b) performed by oral administration of NP (50 and 100 IU/kg of insulin) in diabetic rats, 
which changes in plasma glucose were compared with subcutaneously administration of free 
insulin at 2.5 IU/kg and orally administration of empty NP, and the results showed an 
effective decrease of the blood glucose levels at administrated doses by insulin-NP.  
A crucial issue for successful development of this therapy is to understand and control 
the biodistribution of NP, which can provide valuable information early in the development 
of this approach. This importance has created a demand for techniques that can analyze the 
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information not only qualitatively but also quantitatively. Biodistribution studies can be 
carried out in animals by measuring the radioactivity of labelled compounds by nuclear 
medicine techniques. It gives an indication of global tissue accumulation patterns, which helps 
the design and the optimization of formulation. In addition, the ability to provide non-
invasive, three dimensional and quantitative data inherent to nuclear medicine has become a 
relevant assay for biologic characterization, to drugs screening, optimization and biological 
safety (LIU, 2012; McCONVILLE, 2013). 
1.5 Nuclear Medicine 
Nuclear medicine is defined as a medical specialty that uses unsealed sources of 
radiation in the diagnosis and treatment of diseases. The role of nuclear medicine in clinical 
diagnosis is due to its ability to detect function with great sensitivity generating a functional 
image that shows the body´s biochemistry, taking in account the radiopharmaceutical 
chosen. For this reason nuclear medicine has contributes not only to clinical diagnosis but 
also to the understanding of disease mechanisms (LENTLE, 2003; SHARP, 2005). In nuclear 
medicine, functional information is resulted from the distribution of a radiopharmaceutical 
administered to the patient, usually by intravenous injection. By labelling a pharmaceutical 
with a radionuclide, the biodistribution of this radiopharmaceutical can be measured, only by 
the amount of radioactivity present (SHARP, 2005). Thus, nuclear medicine is a technique 
that is intrinsically functional because it measures the radiation emitted by a tracer specific to 
a particular function and, therefore, the location and concentration are directly related to 
the specific function (LENTLE, 2003). A radiopharmaceutical is a radioactive compound, 
without or with a minimal pharmaceutical effect due to low concentration that is used. Thus, 
it is used in nuclear medicine for diagnosis and treatment of human diseases, however 95% 
of the radiopharmaceuticals have a diagnostic purpose (SAHA, 2004a). The usefulness of a 
radiopharmaceutical is dictated by the characteristics of the radionuclide and the 
pharmaceutical. In a radiopharmaceutical design, the pharmaceutical is chosen on the basis of 
its preferential localization in a given organ or its participation in a specific physiologic 
function. After, a suitable radionuclide is added to the chosen pharmaceutical to form a 
radiopharmaceutical which after administration will emit radiations that are detected by a 
external radiation detector. Thus, the physiologic function and sometimes the morphologic 
structure of the organ or system can be assessed. Radiation from the radionuclide chosen 
should be easily detected by nuclear medicine instruments, and the radiation dose to the 
patient should be as low as reasonable available, according to ALARA principle. A 
radiopharmaceutical should obey some characteristics, such as easy availability, short 
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effective half-live, high target non-target activity ratio and radioisotopes adequate for the 
purpose, γ-rays emitters are preferable to image acquisition in conventional cameras-gamma, 
positron emitters are used to positron emission tomography (PET) acquisitions and α and β 
emitters are useful for the therapeutic purpose (SAHA, 2004a).   
1.5.1 Nuclear Medicine Techniques 
The term “nuclear medicine” comprises different imaging techniques ranging from PET 
and single photon emission computed tomography (SPECT) through a whole body planar 
images or “scans” (LENTLE, 2003).  
Nuclear medicine images are generated by the detection of gamma-rays, X-rays or 
annihilation quanta. The cameras crystals detect the density of gamma-rays emitted per unit 
area and in the case of single photon emitters the direction of flight is determined by 
geometric collimation (SAHA, 2004a).  
Scintigraphic instrumentation consists of scintillation crystals to convert gamma-ray into 
visible light, suitable light sensors (photomultiplier tubes), readout electronics and image 
processing units. Scintillators emit light after the gamma photon has deposited its energy in 
the crystal. NaI(Tl) (sodium iodide with thallium doping) scintillation crystal is often used in 
nuclear medicine because of its high light output, reasonable decay time that makes this 
crystal the choice for single photon detection with energies of 70-360keV (detection 
efficiency of 90% for 140keV) (MAHER, 2004; SAHA, 2004a).  
Since the emission of gamma-rays is isotropic, collimation is needed to restrict data to 
gamma-rays of defined directions. Collimator design always is a balance between spatial 
resolution and sensitivity: reducing the size of the holes or using longer septa improves 
spatial resolution but reduces sensitivity at the same time. This fact is the most important 
tradeoff in the imaging process using Anger cameras (MAHER, 2004). 
Positron emission tomography (PET) utilizes the unique feature of two high-energy 
annihilation-rays emitted back-to-back after positron interaction. Detector pairs count all 
events which occur in both of them within a very short time interval (10-20 ns). From data 
along these lines of response, the distribution of radioactivity can be reconstructed by 
mathematical methods (MAHER, 2004; SAHA, 2004b).  
Therefore, as previously mentioned, radionuclide is chosen depending on the image 
technique. For PET acquisition, the most used positron emitter is 18F, and its use to label 
Fluorodeoxyglucose (FDG) has propelled this technique. This radiopharmaceutical allows to 
evaluate cells glycolytic activity, since it is a glucose analogue. Thus, 18F-FDG uptake in cells 
reveals its viability and proliferation rate. The accurate of the PET/CT with 18F-FDG make 
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this radiopharmaceutical the gold standard for oncologic applications. Besides, 18F-FDG has 
first used in neuroscience and cardiology (COLEMAN, 2006). The search for new 
radiopharmaceuticals for PET images have widely increase and other radiopharmaceuticals 
have been approved for myocardial perfusion, like 82Ru and 13N-ammonia, for protein 
synthesis, such as 11C-acetate, and for neuroendocrine tumors, such as 68Ga-DOTATATE 
(68Ga-DOTA-DPhe,
1Tyr3-octreotate) (JADVAR, 2005; KAYANI, et. al., 2008).  
 The conventional nuclear medicine has application in all of biologic systems and the 
radiopharmaceuticals routinely used to clinical diagnostic are assorted. In this field many 
radionuclides are used, such as, 201Tl, 123I, 67Ga, 111In and 99mTc. Among these radionuclides, 
technetium-99m is the most attractive to the nuclear medicine physician because of its 
optimal gamma energy for SPECT, its availability, its relatively low cost, and its easy-to-label 
kit preparations for in-house use. Another advantage is the low radiation burden to patients, 
due primarily to its short half-life. Ideally, the half-life should not be very short to avoid that 
the activity have decayed to a very low levels before the image begin. On the other hand, if it 
is too long the patient will remain radioactive for a considerable time and in order to reduce 
the possibility of radiation damage the amount of activity administered should be kept low. 
The decay within hours also facilitates the handling of waste (PERSSON, 1969; 
YOKOYAMA, et. al., 1975; SHARP, 2005).  
1.5.2 99mTc-radiopharmaceuticals 
The 99mTc-labeled compounds constitute more than 80% of radiopharmaceuticals used in 
clinical nuclear medicine. Technetium is a transition metal of VIIB group of the periodic table, 
it has an atomic number of fourty-three and it was discovered in 1937 by Perrier and Segré. 
There are twenty-five isotopes and ten isomers of technetium and the 99Tc is the most 
common. This isotope decays by β- emission with 293KeV of energy and 2,13x105 years of 
half-life (SAHA, 2004a).  
The technetium-99m is a radionuclide often used in single photon emission Nuclear 
Medicine due to its several physical and chemical factors such as approximate monoenergetic 
gamma decay (140 - 142 keV), high photon flux detected efficiently by the NaI(Tl) crystals of 
the gamma-cameras which allows image acquisition with good resolution. Technetium-99m is 
a nuclear isometric state of technetium-99 with a half-life of 6.01 hours, that also represents 
a favorable characteristic for the patient dosimetry (MAHAMOOD, 2003; SAHA, 2004a; 
DESCRITOFORO, 2007).  
The technetium-99m is an artificial element obtained by 99Mo/99mTc generator in which 
99Mo (t1/2=65.94 hours) decays to 
99Tc. This radionuclide system made technetium-99m 
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available for clinical use and research and has stimulate the development of compounds with 
considerable impact on radiochemistry and nuclear medicine. An efficient separation makes 
possible to obtain 99mTc with high specific activity in aqueous solution as sodium 
pertechnetate (Na99mTcO4
-), represented in figure 8. The pertechnetate ion is obtained in a 
+7 oxidation state; with a tetrahetral geometry, the Tc+7 stays in the center and the oxygen 
in each vertex of tetrahedron.  
 
 
 
 
 
 
Thus, this oxidation state of technetium does not promotes the formation of complexes 
with chelates or ligands which makes necessary to reduce it (SAHA, 2004a; 
DESCRITOFORO, 2007).  Eight oxidation states (-1 to VII) are possible, and the most 
stable states are (VII), (V), (IV), (III), (I) and (0), and these states, conjugated with several 
coordination geometries, confers to this compound a rich and versatile chemistry (RHODES, 
1974; BANERJEE, 2001; MAHAMOOD, 2003). The majority of 99mTc radiopharmaceuticals 
contains technetium as Tc(V) (SAHA, 2004a; DESCRITOFORO, 2007). 
Concerning 99mTc radiopharmaceuticals applications, there are perfusion agents, such as 
99mTc-MIBI (99mTc-methoxyisobutyl isonitrile) for myocardium perfusion or 99mTc-ECD (99mTc-
ethyl cysteinate dimer) for brain perfusion; bone agents such as 99mTc-diphosphonates; renal 
agents, such as 99mTc-DTPA (99mTc-diethylenetriaminepentaacetate) and 99mTc-MAG3 (
99mTc-
mecraptoacetyltriglycine); lung agents, such as 99mTc-MAA (99mTc-macroagregates of human 
serum albumin); and oncologic agents, such as 99mTc-diphosphonates often used for bone 
metastasis, 99mTc-HSA nanocolloid (99mTc-human serum albumin nanocolloid) for sentinel 
lymph node scintigraphy (ZOLLE, 2007).  
Along the years many have been the radiopharmaceuticals approved for use in nuclear 
medicine, but, one the other hand, there are radiopharmaceuticals that are used anymore, 
such as 99mTc-HSA. Biodistribution of HSA labeled with technetium-99m after intravenous 
administration had a similar behavior to the patient’s own serum albumin and served as a 
suitable tracer for the vascular compartment. Eventually, labeled albumin could be used for 
studies of nuclear angiography, gated cardiac blood-pool, albumin metabolism, direct 
placental visualization, cisternography and gastrointestinal-blood-loss, and it was readily 
available in the end of the 60´s and beginning of the 70´s (PERSSON and LIDÉN 1969; 
Figure 8 – Schematic representation of chemical formula of Na99mTcO4-. Exported by Saha, 2004a.   
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RHODES, 1974). Plasma-derived HSA (pHSA) was clinically used to correct circulating 
plasma volume and improve colloid osmotic pressure. Nevertheless, pHSA supply was 
limited as it was manufactured from a fractionation of donated human plasma. This 
nonautologous multisource approach introduced significant risks of allergic reactions and 
contamination by blood-derived pathogens, such as human immunodeficiency virus (HIV), 
viral hepatitis, and Creutzfeld-Jakob disease prions (WANG, et. al., 2011). For these reasons 
the nuclear medicine studies with albumin were abandoned (RHODES, 1974; WANG, et. al., 
2007). Although, the HSA is again available to nuclear medicine applications, 99mTc-HSA was 
replaced by 99mTc-RBC (99mTc-red blood cells) for nuclear angiography and by cardiac agents 
for the gated cardiac blood-pool (ZOLLE, 2007). 
1.5.3 Albumin radiolabeling 
Protein binding is greatly influenced by a number of factors, such as its charge, pH and 
nature. The nature of a protein, particularly its content of hydroxyl, carboxyl, and amino 
groups and their configuration in the protein structure, determines the extent and strength 
of its binding to the radioisotope. In general, in a radiolabeling procedure should be into 
account the compatibility between the drug and the isotope, the stability, the solubility, the 
biodistribution, plasmatic proteins binding, the size and the charge of the drug (SAHA 
2004a).  In an isotope exchange reaction, one or more atoms in a molecule are replaced by 
an isotope of the same element, having different mass numbers. Since the radiolabeled and 
parent molecules are identical except for the isotope effect, they are expected to have the 
same biologic and chemical properties (SAHA, 2004a).  
Yuh-Feng Wang et. al. have been developed a 99mTc-HSA preparation technique using 
autologous albumin, which was radiolabeled by stannous chloride method (WANG, et. al., 
2007; WANG, et. al., 2011). As previously mentioned, chemically, Na99mTcO4
- is a 
nonreactive specie and does not label any compound by direct addition. In 99mTc-labeling of 
many compounds, prior reduction of 99mTc from the 7+ state to a lower oxidation state is 
required. Various reducing agents have been used, such as stannous citrate, stannous 
tartrate, concentrated hydrochloride acid (HCl), sodium brohydride, dithionite, ferrous 
sulfate and stannous chloride. Among these, stannous chloride is the most commonly used 
reducing agent used in the most preparation of 99mTc-labeled compounds. The oxidation 
state of technetium in 99mTc-HSA is not known with certainty, but has been postulated to be 
5+ (SAHA, 2004a). The advantages of stannous salts for kit formulation have been 
demonstrated, and the stability of kits was increased by their lyophilization because stannous 
salts are nontoxic and stable when lyophilized and kept in a nitrogen atmosphere. The 
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feature that makes it so interesting for 99mTc-radiopharmaceutical preparation is the easiness 
of the stannous ion (Sn2+) to be oxidized to tin (IV) according to the reaction: 
Sn2+ → Sn4+ + 2e-  
The amount of stannous chloride is empirically optimized for each individual kit 
formulation, maintaining the balance between two parameters: (1) a large excess of stannous 
chloride should be used according to the added pertechnetate activity and (2) the amount of 
stannous chloride should be kept as low as possible in order to avoid further reduction of 
pertechnetate to a lower oxidation state. Moreover, the level of tin impurity in the 
radiopharmaceutical should be kept as low as possible (DESCRITOFORO, 2007).  
The products of the pertechnetate reduction depend on the strength of the reducing 
agent, the affinity of the available complexing groups and its concentration. Since hydroxide 
and water have high affinity for reduced technetium and compete with other complexing 
groups, the reaction’s products are greatly influenced by pH (RHODES, 1974; BANERJEE, 
2001; MAHAMOOD, 2003). In any case, pertechnetate is a weak oxidant, in acid medium, 
and it is reduced by weak reductants. Sometimes, an excess of ligand may also act as 
reducing agent (SAHA, 2004a). 
There is a possibility that reduced 99mTc may undergo hydrolysis in aqueous solution. In 
this case, reduced 99mTc reacts with water to form various hydrolyzed species depending on 
the pH, duration of hydrolysis and presence of other agents. An analysis of chemical reaction 
shows that hydrolysed technetium is a compound of 99mTcO2 complexed with other 
ingredients (e.g., stannous oxide, molybdenum trioxide or aluminum). This hydrolysis 
competes with the chelation process of the desired compound and thus reduces the yield of 
99mTc-radiopharmaceutical (SAHA 2004a). The use of stannous chloride has a disadvantage 
due to the Sn2+ ion also readily undergoes hydrolysis in aqueous solution and forms insoluble 
colloids. These colloids bind to reduced 99mTc and thus compromise the labeling yield 
(SAHA, 2004a). 
Besides the stannous chloride method for albumin radiolabeling, the use of ascorbic acid 
and iron chloride for the labeling of HSA with 99mTc was suggested by Harper and the 
method was developed by Stern, Zolle and McAfee. This method was based on pH changes 
along the process, what difficult its reproducibility (RHODES, 1974).  
1.5.4 Quality Control 
Radiopharmaceuticals must comply with both radiation and pharmaceutical standard, in 
order to ensure their safe and efficacious use. The in vivo behavior of the 
radiopharmaceutical is dependent upon its quality, which demands high standards of 
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radionuclide, radiochemical and chemical purity or particle sizing concerning suspensions. 
Injections must satisfy additional standards for sterility, apyrogenicity and free from foreign 
particulate matter (I.A.E.A, 2006). The quality control tests fall into two categories: 
physicochemical tests and biological tests. The physicochemical tests indicate the level of the 
radionuclide and radiochemical impurities and determine the pH, ionic strength, osmolality, 
and physical state of the sample. The biological tests establish the sterility, apyrogenicity and 
toxicity of the material (SAHA, 2004c).  
All radiopharmaceuticals should have an appropriate hydrogen ion concentration or pH 
value for their stability and integrity. Thus, any deviation from the desired pH must be 
considered with caution and should be solved (SAHA, 2004c).  
The radiochemical purity of a radiopharmaceutical is the fraction of the total 
radioactivity in the desired chemical form. Radiochemical impurities arise from 
decomposition due to the action of solvent, change in temperature or pH, light, presence of 
oxidizing or reducing agents, and radiolysis (SAHA, 2004c). Examples of 99mTc radiochemical 
impurity in 99mTc-labeled complexes are 99mTcO4
- and reduced-hydrolyzed 99mTc (99mTc-RH). 
The presence of radiochemical impurities in a radiopharmaceutical results in poor-quality 
images due to the high background from the surrounding tissues and the blood, and provides 
unnecessary radiation dose to the patient. To overcome these limitations the radiochemical 
purity should be superior to 90 % (SAHA, 2004c). 
To evaluate the radiochemical purity of a complex, there are many separation 
techniques, but the rapid radiochemical separations (procedures that can take seconds to 
minutes) are the most used since many interesting radionuclides used in nuclear medicine 
studies have short half-lives. To determine the radiochemical purity, of technetium 
radiopharmaceuticals, ascendant instant thin-layer chromatography or paper 
chromatography are the most used techniques (MAHER, 2004). Radiochemical impurities are 
detected using a two-step process: firstly, radiochemical species are separated based on 
differences in chemical characteristics, and secondly the radioactivity associated with each 
chemical species is assayed using an appropriate radiation measuring device (I.A.E.A., 2006; 
ELSINGA, 2010).  
During the chromatographic process, different components of the sample distribute 
themselves between the adsorbent stationary phase and the mobile phase (solvent), 
depending on their distribution coefficients (Rf). Electrostatic forces of the stationary phase 
tend to retard various components, while the mobile phase carries them along. This effect 
and the varying solubilities of the different components in the mobile phase cause the 
individual components to move at different speeds and to appear at different distances along 
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the paper or ITLC strip. The polarity of the solvent also affects the chromatographic 
separation of components in a sample. In paper chromatography or ITLC, each component 
in a given sample is characterized by an Rf value, which is defined as the ratio of the distance 
traveled by the component has advanced from the original point of application of the test 
material to the distance of the solvent front (usually Rf value is represented in a scale 
between 0 to 1) (SAHA, 2004c; DESCRITOFORO, 2007).  
It should be noted that radiochemical purity may not be constant, but may change owing 
to radiolytic decomposition, oxidation-reduction reactions, and interaction with 
contaminants or stopper/container components, among other factors (ELSINGA, 2010).  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
2. Aim 
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This thesis aimed the biodistribution study of BSA-NP by nuclear medicine techniques. 
Therefore, the following aims were defined: 
- Optimization of  BSA-NP radiolabeling with 99mTc; 
- Optimization of 99mTc-BSA-NP quality control by ascendant micro-cromathography; 
-  Study the biodistribution of 99mTc-BSA-NP, based on a comparative study between 
99mTc-BSA-NP and 99mTc-BSA biodistribution.
  
 
  
  
 
 
 
 
 
 
 
 
 
 
3. Material and Methods 
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To improve NP formulation one of the critical points was their behavior in vivo and the 
nuclear medicine was a possible approach to study biodistribution. To apply this imaging 
technique it was necessary to add a radionuclide to the object of study, in this case the NP. 
As the BSA was the most external coating, the labelling of BSA with 99mTc was the first 
approach. The radiolabeling method to obtain 99mTc-BSA with high radiochemical purity was 
optimized.  
3.1 Materials  
3.1.1 NP production 
Low viscosity sodium alginate (viscosity of 1% solution at 25ºC, 4-12 cps), dextran 
sulfate, dextran sulfate, Span® 80, the lipofilic emulsive agent (sorbitan monooleate, 
HBL = 4.3) and BSA were provided from Sigma-Aldrich (Steinheim, Germany). Micronized 
calcium carbonate (Setacarb®; 97% of particles with less than 2 µm) was supplied by Omya 
(Orgon, France). Liquid paraffin (viscosity = 190 mPa.s) was provided by Scharlau (Spain). 
Human insulin, with recombinant origin and quick action (Actrapid® 100UI/mL) was obtained 
from Novo Nordisk A/S (Bagsvaerd, Denmark). Desionized water required in the 
preparation of the solutions was obtained from a Millipore Elix 5 system (Bedford, MA, 
EUA). The other reagents used were analytical grade. 
3.1.2 Quality control 
ACD (acid citrate-dextrose) was prepared by dissolving 11.3 g of sodium citrate 
dehydrated (Na3C6H5O7.2H2O), 4.0 g of citric acid monohydrate 
[C(OH)(COOH)(CH2.COOH)2.H2O], and 11.0 g of D-glucose (C6H12O6) in a final volume of 
0.5 L of distilled water and sterilized by autoclaving. Acetone and methanol were purchased 
from Sgima Aldrich®.  
The Whatmann No.1 strips and Whatmann 31 ET strips were provided from 
Whatmann Chromatography Products; the aluminum SG 60 strips (Art. 5553 DC-Alufolien 
Kieselgel 60) were supplied by MERCK®; finally the aluminum oxide IB-F strips were 
obtained from J.T. BAKER®. ITLC-SG was supplied by ITLC-SG, Pall Corporation. 
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3.1.3 BSA radiolabeling 
The pH was measured by pH-Fix 0-6.0, Machenerey-Nagel. Stannous chloride was used 
in this formula Sn2Cl.2H20, which was purchased by Aldrich
®, it was dissolved in purged 
ultra-pure water with Argon gas atmosphere and in HCl. The ascorbic acid (C6H6O6) from 
the Sigma® was used in and it was dissolved in ultra-pure water purged with Argon gas 
atmosphere. The sodium thiosulfate was used in crystal form and it was obtained from Sigma 
Aldrich®. It was dissolved in ultra-pure water to the concentration mentioned above. The 
phosphate buffer consists in Na2HPO4.2H2O (3.2mmol) from Merck
® and NaH2PO4 (1.0 
mmol) Merck® dissolved in 50 ml of ultra-pure water. 
The BSA was quantified with Coomassie® Protein Assay Reagent Kit. 
NP size was measured with a Coulter LS130 (Beckman Coulter Inc., Fullerton, CA, 
USA) that has a sensibility between 0.1 and 1000µm.  
 
2.1.4 In vivo studies  
Mice were received from Laboratories Charles River, Inc. and were maintained in 
appropriate and acclimatized room, submitted a cycles of 12 hours of light and with free 
accesses to food (Mucedola 4RFN) and filtered water.  
 
 
  
Radioactive labeling of nanoparticles with albumin to study the biodistribution 
35 
 
3.2 NP production 
The NP used in this work have been developed in other projects carried out with the 
supervision of Professor António Ribeiro et. al. (SARMENTO, et. al., 2007a; SARMENTO, et. 
al., 2007b; WOITISKI, et. al., 2009a; WOITISKI, et. al., 2009b). Thus, the method used to 
produce NP will be briefly described. 
NP were prepared by the emulsification/internal gelation method. The oil phase used 
was paraffin oil and the emulsifier agent was sorbitan monooleate. The aqueous phase was 
constituted by alginate, insulin, poloxamer 188, dextran sulfate and calcium carbonate. The 
emulsion was obtained mixing both phases with marine impellers stirrers, and to promote 
the obtainment of nanodroplets, the emulsion was sonicated. Acetic acid was added to the 
emulsion with paraffin oil drop by drop to trigger the internal gelation of alginate and the 
conditions of stirring and sonication were maintained.   
The recuperation of NP scattered in the W/O emulsion was performed by washing with 
a buffer solution and hexane with an orbital stirring. The separation of the two phases was 
made in a separating funnel through the addition of propanol and ethanol, maintaining the pH 
of 4.5. Then, the organic solvents were eliminated by rotary evaporator and the obtained 
dispersion was sonicated and coated with chitosan followed by the coating with albumin (1% 
(w/v) at pH 5.1). Finally the pH was adjusted to 5.1. 
3.2 Quality control 
Ascendant micro-chromatography is a method often used to determine radiochemical 
purity of technetium-99m radiopharmaceuticals and it allows the molecular and physical 
separation of composts of a sample (SAHA, 2004a). To determine radiochemical purity of 
99mTc-BSA it was necessary to optimize an appropriate quality control.  
3.2.1 99mTc-BSA radiochemical purity optimization 
For ascendant micro-chromatography, a small aliquot of the radiopharmaceutical 
preparation was spotted on a paper strip or on an instant thin-layer chromatography (ITLC) 
strip, which are made of glass fiber impregnated with silica gel (SG) or polysilicic acid (SA), 
for example. Chromatography was carried out by dipping the spotted strip into an 
appropriate solvent contained in a chamber, in such a way that the spot remained above the 
solvent (SAHA, 2004a) 
Thereby, two systems were used to allow the quantification of the three possible 
radiochemical species present in the sample. 
First system allowed isolation of free sodium pertechnetate (99mTcO4
-) whose the mobile 
phase was sodium chloride 0.9 % and solid phase was a strip with 10 cm length and 1 cm 
Fig. 4 – Scheme of the strip used in the first system 
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width of instant thin layer cromatography silca gel (ITLC-SG). The strips were marked with 
fine pencil lines at 1cm (Rf=0), 4.5 cm (Rf=0.5) and 8 cm (Rf=1) from the bottom, as shown in 
figure 9. This system has been used in nuclear medicine to evaluate many 
radiopharmaceuticals due to the hydrophilic characteristics of 99mTcO4
- which allow this 
radiochemical specie go to the top of the strip with the solvent while the other species stay 
in the bottom (SAHA, 2004c).  
 
 
 
 
 
 
 
 
 
 
The second system was tested to separate 99mTc-RH from the pretended radiochemical 
specie, 99mTc-BSA. The tested systems were defined taking into account the methods 
suggested in the bibliography to the 99mTc-HSA and aiming the 99mTc-RH quantification, and 
they are presented in the table I (ZOLLE, et. al., 1973; RHODES, 1974; SAHA, 2004c; 
OZGUR, et. al. 2011).  
  
Figure 9 – Scheme of the strip used in the first system. 
Origin 
Middle  
Top  99mTcO4
- 
99mTc-RH and 99mTc-BSA 
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Table 1 – Systems tested to optimize the determination of radiochemical purity (ZOLLE, et. al., 1973; RHODES, 1974; 
SAHA, 2004c; OZGUR, et. al., 2011) 
 
 
1ACD – Acid citrate-dextrose; 2SG – Silica gel; 3ITLC - Instant thin-layer chromatography. 
 
The strips with 25 cm long were marked with fine pencil lines at 2 cm (Rf=0), 13.5 cm 
(Rf=0.5) and 24 cm (Rf=1) from the bottom of the strip, as shown in figure 10. The strips 
with 10 cm were marked as the strips used in the first system for all stationary phase tested. 
 
 
 
 
Mobile 
Phase 
Stationary 
Phase 
Strip size 
(cm) 
Method 
System A ACD1 
Aluminum SG2 
60 
10 
Paper 
chromatography 
System B ACD 
Aluminum 
Oxide IB-F 
10 
Paper 
chromatography 
System C ACD ITLC3-SG 10 ITLC 
System D ACD ITLC-SG 25 ITLC 
System E ACD 
Whatmman 
31 ET 
10 
Paper 
chromatography 
System F 
Methanol 
85% 
Whatmman 
No.1 
10 
Paper 
chromatography 
System G Acetone 
Whatmman 
No.1 
10 
Paper 
chromatography 
Figure 5 – Scheme of the strips with 25 cm used in the second system. 
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 In general, to carry out the chromatography, an aliquot of radiopharmaceutical was 
placed at the origin of the strip. Then, it was placed in the chromatographic chamber 
previously saturated with the solvent for 15min in such a way that the solvent did not 
contact with the radiopharmaceutical sample. When the solvent achieved the top of the 
strip, this was taken off the chamber and dried at room temperature. To evaluate the 
distribution of each radiochemical impurity, this protocol was done with samples of 
Na99mTcO4
- and 99mTc-RH, separately. The sample of 99mTc-RH was obtained mixing 
Na99mTcO4
- with 1.11M of stannous chloride, freshly prepared.  
The quantification of each specie present on the strip was done by image acquisition to 
the strip with a camera-gamma and the following parameters, 128x128 matrix, 30 seconds of 
acquisition, zoom of 1 and an energy peak of 140keV with an energy window of 15%. The 
images processing was done by marking two regions of interest (ROIs) for each image that 
correspond to two parts of the strip (Rf=0 until Rf=0.5 and Rf=0 until Rf=1). 
The percentage of each component was calculated by the ratio between the counts of 
the isolated component and the total counts of the strip as represented in the equation 1. 
 
         
 
 
                                       
                                      
      Eq.1 
Where, 
- 99mTcO4
- is free pertechnetate; 
- Counts Rf=0.5 to Rf=1 of the first system is obtained by the ROI drawn between 
Rf=0.5 to Rf=1 in the strip of the first system; 
- Total counts strip of the first system is obtained by the ROI drawn in whole strip of 
the first system. 
 
The radiochemical purity in percentage of 99mTc-BSA and 99mTc-BSA-NP was calculated 
by the equation 2. 
% Radiochemical purity = 100 – (% 99mTcO4
- + % 99mTc-RH)  Eq. 2 
Where, 
- 99mTcO4
- is free pertechnetate; 
- 99mTc-RH is technetium reduced-hydrolyzed. 
 
The radiochemical purity of 99mTc-BSA complex was measured at 5, 15, 60, 120, 360, 
720 and 1440 minutes after the radiolabeling procedure. Concerning 99mTc-BSA-NP, the 
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radiochemical purity was measured after each step, namely, coating, pH adjustment, 
centrifugation and sonication, which were carried out 45, 50, 60 and 75 minutes after the 
radiolabeling 99mTc-BSA, respectively. Furthermore, 99mTc-BSA-NP radiochemical purity was 
also measured at 120, 360, 720 and 1440 minutes after the radiolabeling of 99mTc-BSA.  
3.3 BSA radiolabelling optimization 
In order to optimize the radiolabeling method used to achieve the labeled BSA with 
99mTc several conditions were tested, namely, albumin mass, the reducing agent and its 
concentration, ascorbic acid concentration, volumetric activity of Na99mTcO4
-, pH, 
temperature, stirring and incubation time. 
The pH was evaluated by color comparison method.  
The albumin tested was the same used in the NP coating and for this reason the 
concentration and pH of the solution were the same. Nevertheless, three quantity of 
albumin was tested, 1, 2 and 5mg.  
In this work the stannous chloride dihydrated was dissolved in purged ultra-pure water 
with Argon gas atmosphere and in HCl, at different concentrations, as indicated in table 2 e 
3. The radiolabeling procedures presented in table 1 and 2 were carried out by adding each 
compound in the following sequence: stannous chloride, BSA and Na99mTcO4
-, after this the 
vial was manually shaken and incubated at room temperature. All vials used in these 
procedures were purged with Argon gas atmosphere before it was used.  
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Table 2 – Conditions tested with stannous chloride dissolved in water and in HCl (RHODES, 1974; WANG, et. al., 2011).  
 
Stannous 
chloride 
(µl) 
 
 
Stannous 
chloride 
(mmol) 
BSA1 
 (mg) 
 
 
Na99mTcO4
-  2 
(MBq/ml) 
Protocol 
Stannous 
chloride 
dissolved in 
water 
200  8.86x10-4 
1  
592 A 
1110 B 
2  
592 C 
1110 D 
Stannous 
chloride 
dissolved in 
HCL 
10  10 0.44x10-4  93 E 
1BSA – Bovine serum albumin; 2Na99mTcO4- - Sodium pertechnetate 
 
The adding of ascorbic acid was carried out to improve the radiolabeling efficiency. It 
was added after the stannous chloride, following the sequence above mentioned in the 
table 3. 
 
Table 3 - Conditions tested with stannous chloride and ascorbic acid dissolved in water (ZOLLE, et. al., 1973; RHODES, 
1974; YOKOYAMA, et. al., 1975). 
 Stannous chloride Ascorbic Acid 
 
 
BSA1 99mTcO4
-  2 Protocol 
 µl  mmol µl  Mmol  mg MBq/ml  
Stannous 
chloride 
dissolved 
in water 
400  1.8x10-3 
500  2.8x10-3  
1 
111 F 
296 G 
592 H 
5 
111 I 
296 J 
500  14.2x10-3  
1 111 K 
5 
111 L 
296 M 
 
 
 
 
1BSA – Bovine serum albumin; 2Na99mTcO4- - Sodium pertechnetate 
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Nevertheless, the influence of temperature was tested in protocol N, heating at 40˚C 
for ten minutes follow the protocol J procedure.   
The pH influence was tested with the composition of protocol J. It was carried out with 
a decreasing of pH to 2 before the addition of Na99mTcO4
- as it also had a pH of 2 
(protocol O). This protocol was repeated with pH values of 1 (protocol P).  
Thus, other method to radiolabeling BSA with Na99mTcO4
- was carried out. It consists in 
a mixture of sodium thiosulfate 10 mg.ml-1; HCl, N; and 1110 to 2220 MBq of Na99mTcO4
-
 
(1.0/1.0/0.5) (v/v/v) that is heated at 100˚C for 3.5 minutes with a dry bath. At the end of this 
time the vial was cooled in running water for 5 minutes to low the temperature to room 
temperature. Then, 2.5 ml of BSA was added and the vial was stirring with vortex for 30 
seconds. Finally, 2 ml of pH 7.4 phosphate buffer was added and the vial was manually shaken 
(PAOLI ,et. al., 1966; CRAGIN, 1969).  
3.3.1 NP radiolabeling 
In respect to the radiolabeling of the NP, these were coated with the 99mTc-BSA in spite 
of radiolabeling the BSA after incorporating in the NP. To coat NP the pH of 99mTc-BSA was 
adjusted to 5.1 (15 minutes after the radiolabeling) and the procedure was performed with 
the same conditions used to coat the NP with BSA. At this point the NP were centrifuged at 
56 g for 5 minutes; these conditions were optimized with tests made to eliminate the BSA 
that did not interact with the NP, as described below. Following, the NP were sonicated 
(A=50 KHz) for 10 minutes.   
3.3.1.1 Optimization of the parameters to the centrifugation  
To evaluate the best condition to centrifuge NP and eliminate the unloaded BSA, 
different conditions were tested and the quantification of BSA present in the supernatant 
was performed with Coomassie® Protein Assay Reagent Kit. The test was executed with 
insulin-free NP since the kit reacts with proteins indiscriminately. The conditions tested 
were the following: (1) 5585 g for 10 min; (2) 1396 g for 10 min; (3) 56 g for 10min; (4) 56 g 
for 5min. The protocol for the quantification allowed a working range from 1 µg to 25 µg of 
BSA and it consisted in mixing 5 µl of the sample with 250 µl of the Coomassie Reagent and 
incubate for 10 min at room temperature; the absorbance was measured at 595 nm and the 
average reading for the blank replicates was subtracted from the samples replicates.  All 
measurements were performed in triplicate. To determine the protein concentration of each 
sample, a standard curve was prepared by plotting the average blank-corrected 595 nm 
reading for each BSA standard concentration in µg/mL.   
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3.3.2 NP characterization 
To ensure similarity between NP and 99mTc-BSA-NP, a study to compare these NP 
relatively to their size and zeta potential was designed. Thus, the procedure done to 
radiolabel BSA and to coat the NP was carried out with an eluate 8 days old. Thereby, BSA 
was labelled with 99Tc and, since the dose calibrator does not have sensibility to measure 
such a low activity, the activity of 99mTc present in the sample was calculated theoretically by 
the equation 3.  
A = A0e
-λt      Eq. 3 
Where, 
- A is the acivity (MBq), 
- A0 is the initial activity (MBq), 
- e is the base of the natural logarithm, 
- λ is the decay constant, and 
- t the time in days. 
 
A = 925e-2.772x8 MBq 
A = 2.16 x 10-7 MBq 
 
The NP and the 99Tc-BSA-NP size was detected, both from the same batch, by laser 
diffraction. The measurements were done in triplicate. 
3.3 In vivo studies 
The purpose of the in vivo studies was determining the behavior of the NP in their local 
of administration and its biodistribution, with particular attention to the gastrointestinal 
tract. A comparative study between 99mTc-BSA-NP and 99mTc-BSA was carried out through 
the oral administration of both radiopharmaceuticals to characterize the remaining time in 
the gastrointestinal tract, the adhesion to the intestinal wall and the absorption to the 
bloodstream. The radiopharmaceutical was administrated by gavage as represented in figure 
11. The studied animals were maintained with its habitual food and water and they were not 
sedated in order ensure the physiologic gastrointestinal transit.   
Radioactive labeling of nanoparticles with albumin to study the biodistribution 
43 
 
 
 
An image in posterior projection was acquired and the animals were killed by cervical 
dislocation, according to the legislation, at 0, 30, 60, 90, 120, 180, 360 and 1440 minutes 
after the administration. At this time the gastrointestinal tract, the thyroid, the lungs, the 
liver, muscle, the kidneys and blood were collected and an image was acquired. The 
gastrointestinal tract was divided in order to individualize the stomach, the duodenum, the 
small intestine (jejunum and ileum) and the large intestine. For each portion the content was 
separated from the wall and placed in an individual container. All the portions of the wall 
were individually washed in running water in an appropriate washstand to the procedure, 
and placed in an individual container. Images were acquired from each gastrointestinal 
content and from the wall and their mass (mg) was obtained, as well as, the mass (mg) of all 
organs and fluids collected. All the images were acquired with a gamma-camera (GE 400 AC) 
collimated for a low energy high resolution (LEHR) collimator and controlled by an 
acquisition computer Genie Acq. All the images were acquired with the same parameters, 
namely, 256x256 matrix, 2 minutes of acquisition, zoom of 2 and an energy peak of 140keV 
with an energy window of 15%. The images were transferred to the Xeleris work station to 
be processed. The image processing consisted of the calculation of the total counts of the 
ROI drawn in each mouse image after the radiopharmaceuticals administration over the 
organs, the fluids, the gastrointestinal content and the walls to obtain activity/time curves, 
and to calculate the percent of the activity administered per mass unit (%AA/mg) according 
to equation 4. 
                           
               
                               
     Eq. 4 
Where, 
- Total counts is value obtained for the ROI drawn in the images of each organ, fluid, 
GI content or GI walls; 
- mg is the weight of each organ, fluid, GI content or GI walls 
- Counts of activity administered is counts obtained in the ROI drawn in the image  
Figure 6 – Gavage administration 
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The animal killed 24 hours after the administration, was placed in an individual cage with 
a known weight which image was acquired at the same time of the sacrifice. These images 
were acquired with the same parameters of acquisition used to the other images acquired in 
the in vivo studies and the processing done was the same, as well.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Results 
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According to the methods previously described this chapter presents the results 
obtained concerning the radiolabeling of 99mTc-BSA, its quality control, and the 
biodistribution of 99mTc-BSA-NP using Balb/c mice comparing to the biodistribution of 
99mTc-BSA.   
4.1 Quality Control 
First the quality control was optimized in order to evaluate the radiochemical purity. 
The ascendant micro-chromatography allows separate the different radiochemical species 
according to the chromatographic system used. The results to the different systems tested 
are present in table 4.  
Table 4 – The 99mTcO
4
- and 99mTc-RH Rf for each system tested. Composition of each system was previously 
described in table 1, page 37.  
System 99mTcO4
- (Rf
1) 99mTc-RH (Rf) 
A 0.0 0-1 
B 0.5-1.0 0.0 
C 1.0 0-1 
D 1.0 0.5-1.0 
E 0.5 0-1.0 
F 0.5 0.0 
G 1.0 0.0 
1Rf – distribution coefficient 
The chromatographic systems tested aimed to isolate the 99mTcO4
- and the 99mTc-RH 
from the 99mTc-BSA, in order to calculate de labeling efficiency of the 99mTc-BSA complex. 
According to table 4, for the seven systems tested, the systems C, D and G present a 
high affinity to 99mTcO4
-. This affinity is lower in the system B since, the mobile phase does 
not carry the whole of 99mTcO4
- to the top of the strip. The systems E and F show some 
affinity to 99mTcO4
- but only the middle of the strip was achieved. System B, F and G do not 
have affinity towards 99mTc-RH that is higher in the systems A, C and G, although it is 
insufficient to carry the whole of this radiochemical specie to the top of the strip.   
Since, the 99mTc-BSA presents Rf equals to zero, which is due to its high molecular 
weight the system D has the best performance, because it allow separating radiochemical 
impurities from the radiochemical pretended specie and calculate the radiochemical purity of 
the radiopharmaceutical. Thus, the percentage of radiochemical impurities in the sample was 
calculated according to the following equation (equation 5). 
                    
 
 
                                         
                                       
     Eq. 5 
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Where, 
- 99mTc-RH is technetium reduced-hydrolyzed;  
- 99mTcO4
- is free sodium pertechnetate; 
- Counts Rf=0.5 to Rf=1 of the second system (system D) is obtained by the ROI 
drawn between Rf=0.5 to Rf=1 in the strip of the second system;  
- Counts strip of the second system is obtained by the ROI drawn in whole strip of the 
second system. 
 
4.2 Radiochemical purity of 99mTc-BSA  
With the aim of optimizing the radiolabeling of BSA with Na99mTcO4
- different protocols 
were tested as described in chapter 3. Experimental conditions tested were pH, reducing 
agents, concentration of the kit components, labelling temperature. The radiochemical purity 
obtained for each protocol is displayed in table 5.  
Table 5 – Results obtained to the different radiolabeling protocols tested (n=1). The radiochemical purity (percentage) 
excludes the percentage of 99mTcO4- and 99mTc-RH present in each sample. Composition of each system was previously 
described in tables 2 and 3, page 40. 
Protocol 
Radiochemical 
Purity (%) 
Time after 
radiolabeling 
(minutes) 
Time of 
stability 
(minutes) 
pH 
A 92.0 30 <30 6 
B 89.7 30 <30 6 
C 93.7 30 <30 6 
D 94.1 30 <30 6 
E 28.2 30 30 3 
F 70.3 300 240 5 
G 82.6 120 60 5 
H 68.8 180 <30 5 
I 86.1 360 <30 5 
J 22.2 30 240 5 
K 19.9 30 120 4 
L 26.9 30 360 4 
M 23.4 30 360 4 
N 27.1 15 360 5 
O 87.2 120 60 2 
P 32.2 30 240 1 
Q 95.8 30 360 2 
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The results present in the table 5, reveal that the protocols A, C, D and Q have 
radiochemical purity higher than 90% as it is requested to a radiopharmaceutical for clinical 
use. However, these formulations have different stability after radiolabeling. As a matter of 
fact, the protocol Q reveal the best results due to its radiochemical purity higher than 95% 
achieved 30 minutes after the radiolabeling and high stability over 360 minutes studied. 
Following the selection of protocol Q, a detailed study in order to evaluate the 
reproducibility of the results, as well as the influence of pH changes in the stability of the 
radiochemical purity, was performed. The results are shown in figure 12 and in table 6. 
 
 
 
 
 
 
 
 
 
 
 
The radiochemical purity of 99mTc-BSA achieves the maximum value around 96% five 
minutes after the radiolabeling that is maintained during 300 minutes. At 720 minutes after 
the radiolabeling the radiochemical purity still higher than 90% and the minimum value 
occurs at 1440 minutes.  
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Figure 12 – The percentage of 99mTc-BSA, 99mTcO4- and 99mTc-RH obtained with protocol Q (n=6). 
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Table 6 - The percentage of 99mTc-BSA, 99mTcO4- and 99mTc-RH obtained with protocol Q (n=6). 
Time 
(minutes) 
% 99mTc-BSA 
(mean ± SD1) 
% 99mTc-RH 
(mean ± SD) 
%99mTcO4
- 
(mean ± SD) 
5 96.29 ±1.69 0.56 ±0.56 2.31 ±1.71 
15 96.90 ±1.90 1.00 ±0.95 2.16 ±1.54 
30 96.67 ±1.85 0.97 ±0.89 2.79 ±1.48 
60 96.44 ±1.84 0.95 ±1.08 3.18 ±1.58 
120 95.70 ±1.09 1.34 ±1.12 3.64 ±3.12 
180 95.63 ±1.74 1.35 ±1.13 3.95 ±2.96 
240 95.59 ±1.68 1.37 ±1.11 4.37 ±2.58 
300 95.52 ±1.85 1.40 ±1.10 5.15 ±3.54 
360 93.56 ±3.57 1.41 ±1.24 5.36 ±3.09 
720 90.10 ±2.99 3.66 ±1.14 7.39 ±2.58 
1440 86.04 ±3.66 5.90 ±1.96 9.22 ±3.11 
1SD – standard deviation 
 
After BSA labeling with 99mTc, the NP coating was optimized to be carried out with a 
BSA solution at pH 5.1. Since the pH of the 99mTc-BSA solution obtained with protocol Q is 
2, the increase of pH is required. The influence of pH increase up to 5 is demonstrated in 
figure 12 and in table 7. The pH was increased 15minutes after the radiolabeling, at least.  
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Figure 12 – The percentage of 99mTc-BSA, 99mTcO4- and 99mTc-RH obtained with protocol Q and 
the increase of pH to 5 after 15 minutes (n=8). 
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Table 7 - The percentage of 99mTc-BSA, 99mTcO4- and 99mTc-RH obtained with protocol Q and the increase of pH to 5 after 
15 minutes (n=8). 
Time (minutes) 
% 99mTc-BSA 
(mean ± SD1) 
% 99mTc-RH 
(mean ± SD) 
%99mTcO4
- 
(mean ± SD) 
5 96.60 ±1.58 0.88 ±0.65 2.76 ±1.86 
15 96.85 ±1.48 1.06 ±0.65 2.58 ±1.58 
60 96.48 ±1.58 0.97 ±1.46 3.18 ±1.58 
120 95.49 ±1.75 1.68 ±1.17 3.64 ±3.60 
360 95.58 ±3.68 1.77 ±1.35 5.76 ±3.68 
720 90.59 ±2.58 3.69 ±1.44 7.87 ±2.58 
1440 86.60 ±3.58 5.50 ±1.57 9.73 ±3.77 
1SD – standard deviation 
The influence of increasing pH, on the radiochemical purity, can be observed 60 minutes 
after the radiolabeling. Values still higher than 95 %, around 96 %, so no changes were 
detected comparing to radiochemical purity at pH 2. Therefore, no influence is observed and 
radiochemical purity is higher than 90 % even at 720 minutes after the radiolabeling.  
4.3 NP coating with 99mTc-BSA 
The NP were coated with 99mTc-BSA respecting the coating protocol optimized to these 
NP. Thus, the quality control done to NP was performed to evaluate if the coating protocol 
of NP do not affect the radiolabeling efficiency of 99mTc-BSA. These results are showed in the 
figure 13 and in the table 8. 
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Figure 13 – The percentage of 99mTc-BSA, 99mTcO4- and 99mTc-RH obtained with protocol Q and the increase of 
pH to 5 after 15 minutes. The graphic shows the influence of NP coating protocol with 99mTc-BSA after the NP 
coating at 45minutes, the increase of pH at 50 minutes, the NP centrifugation at 60minutes and the NP sonication 
at 75minutes after the radiolabeling of 99mTc-BSA (n=8). 
Results 
 
52 
 
Table 8 - The percentage of 99mTc-BSA, 99mTcO4- and 99mTc-RH obtained with protocol Q and the increase of pH to 5 after 
15 minutes. The graphic shows the influence of NP coating protocol with 99mTc-BSA after the NP coating at 45minutes, the 
increase of pH at 50 minutes, the NP centrifugation at 60minutes and the NP sonication at 75minutes after the radiolabeling 
of 99mTc-BSA   (n=8). 
Time (minutes) 
% 99mTc-BSA 
(mean ± SD) 
% 99mTc-RH 
(mean ± SD) 
%99mTcO4
- 
(mean ± SD) 
5 96.60 ±1.58 0.88 ±0.65 2.76 ±1.86 
15 96.85 ±1.48 1.06 ±0.65 2.58 ±1.58 
45 95.00 ±1.30 0.60 ±1.00 4.70 ±0.30 
50 94.00 ±4.70 2.80 ±4.20 3.20 ±0.10 
60 96.40 ±2.00 1.70 ±0.80 1.90 ±0.30 
75 96.40 ±1.50 1.60 ±0.80 1.97 ±0.30 
120 95.20 ±0.30 2.50 ±2.30 2.00 ±0.60 
360 95.30 ±0.50 1.30 ±1.00 3.30 ±0.80 
720 90.58 ±2.97 3.69 ±1.44 3.40 ±0.50 
1440 79.40 ±0.40 6.30 ±0.30 13.90 ±0.60 
1SD – standard deviation 
  
The 99mTc-BSA-NP radiochemical purity is bigger than 95 % until 360 min after the 
radiolabeling. It presents a slight decrease to 94 % at 50 min after the radiolabeling when the 
NP pH is increased, however the radiochemical purity returns to values above 96% after the 
centrifugation (60 min after radiolabeling). The radiochemical purity remains bigger than 90% 
until 720 min after radiolabeling and the minimum value is only achieved 1440 minutes after 
the radiolabeling. 
After quality control, the influence of coating protocol of NP with 99mTc-BSA was also 
evaluated in respect of NP size as represented in the figure 14. Both 99mTc-BSA-NP and 
BSA-NP shows a median diameter between 194-198 ± 0.04 nm. As it can be seen, 
99mTc-BSA-NP presents a size distribution curve with more higher-sized particles 
(d90 % = 1870 ± 1659 nm) than BSA-NP (d90 % = 563 ± 5.6 x 10-3). However, the curve 
distribution is slightly altered after BSA-NP radiolabeling.   
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4.3.1 Optimization of the parameters to the centrifugation  
After NP coating with 99mTc-BSA, it is important to ensure that all the existent activity is 
only due to the 99mTc-BSA present in coated NP. Thus, different centrifugation protocols 
were optimized, considering the concentration of BSA present in the supernatant after each 
centrifugation. A calibration curve prepared with BSA standard concentrations in µg/ml was 
obtained with a R2 equal to 0.98. The results obtained for protein quantification in the 
supernatant by using the Coomassie® Protein Assay Reagent Kit in function of centrifugation, 
are described in table 9.  
 
Table 9 – The percentage of BSA present in the supernatant after different after different protocols based on different 
acceleration and time of centrifugation. 
Protocol 
Aceleration 
(g) 
Time 
(minutes) 
 
BSA in 
supernatant 
(%) 
 
1 5585 10  49.22  
2 1396 10  63.50  
3 56 10  65.91  
4 56 5  61.03  
1BSA – bovine serum albumin 
It is possible to observe that the protocol I (5585g during 10 minutes) concentrates the 
lowest percentage of BSA in the supernatant, while the three protocols present higher 
concentrations, and all of them in the same range. 
Figure 14 - Representation of the size distribution, where the complete line corresponds to the NP-BSA and the 
score line corresponds to the 99mTc-BSA-NP. The pH increasing, the centrifugation and the sonication were carried 
out at the same conditions for both.  
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4.4 In vivo studies 
A comparative study between 99mTc-BSA and 99mTc-BSA-NP biodistribution was carried 
out. For each radiopharmaceutical 32 animals were studied. Following oral administration of 
radiopharmaceuticals to animals, biodistribution was assessed by determination of both 
radiopharmaceuticals at different times (n=4 for each time studied). The animals chosen 
were 8-10 week old balb-c male mice, with 22-26g of weight. The activity administered in 
each animal was on average 15.3 MBq (± 2.6 MBq). Following mice sacrifice the 
gastrointestinal tract, organs and fluids were collected and images were acquired in the 
camera-gama. 
This chapter shows the obtained results for 99mTc-BSA and 99mTc-BSA-NP 
biodistribution, first separately and then making comparisons.   
4.4.1 Imaging  
In the in vivo studies the images acquired with camera-gamma were a fundamental tool, 
due to the quantitative data and qualitative information that they can give. At the mice 
sacrifice the gastrointestinal tract were collected and an image was acquired before the 
separation and the cleaning of gastrointestinal contents. The images of the figure 15 and 16 
are exemplified for 99mTc-BSA and 99mTc-BSA-NP, respectively. 
 Figure 15 – The gastrointestinal tract images over time, at 0, 30, 60, 90, 120, 180, 360 and 1440 minutes for 99mTc-
BSA. The number 1 and 2 in each image are anatomical marks, which indicates the stomach and cecum, respectively.  
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Taking into account the qualitative analyses of the images in depicted figure 17 the 
progression of the 99mTc-BSA in the gastrointestinal tract is observed. No activity is detected 
at time 0 and 30 minutes after the administration is possible to appreciate the activity in the 
duodenum and in the initial part of the jejunum. In the next 60 minutes the activity is 
distributed by whole small intestine, which means that it contains the radiopharmaceutical. 
At 120 minutes, the activity arrives to the cecum and then after 60 minutes almost all the 
activity is in the large intestine. The elimination of the radiopharmaceutical of the small 
intestine is almost complete at 360 minutes after the administration. At 1440 minutes no 
activity is seen in the gastrointestinal tract.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The qualitative analyze of the images of figure 18, allows monitoring the progression of 
99mTc-BSA-NP in the gastrointestinal tract. Thirty minutes after the administration is possible 
to see activity in the duodenum and in the jejunum. In the next 60 minutes the 
radiopharmaceutical was spread in small intestine. At 120 minutes after the administration, 
the activity reaches the cecum and followed more 60 minutes almost all the activity is in the 
large intestine. The progression in the small intestine of the radiopharmaceutical is 
Figure 16 - The gastrointestinal tract images over time, at 0, 30, 60, 90, 120, 180, 360 and 1440 
minutes for 99mTc-BSA-NP. The number 1 and 2 in each image are an anatomical mark, which 
indicates the stomach and cecum, respectively.  
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maintained until 360 minutes. Lastly, 1440 minutes after the administration no activity is seen 
in the gastrointestinal tract. 
Furthermore, images of organs and fluids collected and the gastrointestinal walls and 
contents were acquired. The results were obtained through ROIs mapping in these images 
acquired, as illustrated in the figure 17 and 18.  
 
  
 
  
 
 
 
The qualitative and quantitative analyses of the results are complementary for the 
understanding of the radiopharmaceuticals biodistribution. The qualitative analyses of the 
images hardly allow differences between the radiopharmaceuticals. So, these are more 
perceptible with the quantitative date analyses.   
4.4.2 Quantitative analyses of 99mTc-BSA  
Results of 99mTc-BSA biodistribution shows its progression in the gastrointestinal tract 
for 1440 minutes. The percentage of administered activity per mg calculated in different 
organs and fluids studied is shown in the figure 19.  
Figure 7 – ROI mapped in an image acquired after the administration 
Figure 18 - ROIs drawn in the image corresponding to the contents and walls of the gastrointestinal tract, as 
indicated in the image. 
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Figure 19 - Biodistribution in percentage administered activity/mg of 99mTc-BSA in the gastrointestinal contents, 
gastrointestinal walls, liver, thyroid, lungs, muscle, blood and kidneys along the time. 
The exactly values of activity in different samples represented in figure 19 are in 
annex I1. The highest percentage of activity per mg is found in the stomach’s content, 
because it is the local of administration. The activity present in the organs and fluids beyond 
gastrointestinal tract is minimal, as well as, the activity present in the gastrointestinal walls 
showing, however, higher values in the stomach’s wall. The activity present in the stomach’s 
content decreases over time showing total elimination only 1440 minutes after the 
administration, however the activity values after 360 minutes are already residual. The 
activity duodenum’s content reaches a peak 30 minutes after the administration while the 
peak of activity in the small intestine’s content is attained 60 minutes after the administration 
and the progression shows the lower values at 360 minutes. In the large intestine’s content 
the maximum value occurs 120 minutes after the administration but at 360 minutes a 
considerable activity is still present. The complete radiopharmaceutical elimination only 
occurs 1440 minutes after the administration.  
The figure 20 displays the percentage of administered activity per mg for each 
gastrointestinal wall following administration until 360 minutes. 
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The activity present in the stomach’s wall achieves the maximum value at 90 minutes 
after the administration with a marked decrease at 120 minutes. The higher activity in the 
duodenum’s wall is attained at 60 minutes after the administration and 360 minutes after the 
administration there are no activity there. The activity in the small intestine’s wall shows a 
peak at 90 minutes after the administration and at 120 minutes the value of activity returns 
to the baseline values. The large intestine’s wall has a peak of activity 120 minutes after the 
administration that decreases to the base values at 180 minutes.  
Figure 8 - The percentage administered activity/mg of 99mTc-BSA in the gastrointestinal walls. 
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The figure 21 shows the percentage of administered activity per mg of the each portion 
of gastrointestinal tract content for 360 minutes. 
 
As illustrated above, the activity present in the stomach’s content decreases over the 
time, reaching very low values 360 minutes after the administration. The duodenum’s 
content achieves the activity peak 30 minutes after the administration followed by a quick 
elimination and reaching the lower values at 120 minutes. The peak of activity in the small 
intestine’s content is attained 60 minutes after the administration and the lower values are 
obtained 360 after the administration. In the large intestine’s content the maximum value 
occurs 120 minutes after the administration and 360 minutes after a considerable activity is 
still present.   
Other organs and fluids beyond gastrointestinal tract were collected to study the 
intestinal absorption of 99mTc-BSA. The results obtained are shown in the figure 22 where 
we can see that the radiopharmaceutical is only uptaken by the liver. 99mTc-BSA uptake by 
the liver is very low and only occurs 120 minutes after administration and is maintained, at 
least, for more 60 minutes. After 360 minutes radiopharmaceutical uptake is no longer 
observed in the liver. 
Figure 21 - The percentage administered activity/mg of 99mTc-BSA in the gastrointestinal contents. 
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The ROIs drawn in the images of the cages reveal a percentage of administered activity 
per mg equals to 0.0485(±0.0010) that corresponds to the eliminated contents (data not 
shown).  
4.4.3 Quantitative analyses of 99mTc-BSA-NP 
After coating the NP with 99mTc-BSA, the results of 99mTc-BSA-NP biodistribution show 
its progression in the gastrointestinal tract for 1440 minutes. The percentage of 
administered activity per mg in the different organs and fluids studied is shown in figure 23. 
 
 
Figure 22 - The percentage administered activity/mg of 99mTc-BSA in the liver. 
Figure 23 - Biodistribution in percentage of administered activity/mg of 99mTc-BSA-NP. 
Liver
0 30 60 90 12
0
18
0
36
0
14
40
0.0000
0.0001
0.0002
0.0003
Liver
Time (minutes)
%
 A
ct
iv
it
y 
A
d
m
in
is
te
re
d
/m
g
Time (minutes) 
%
 A
d
m
in
is
te
re
d
 a
ct
iv
it
y/
m
g 
Radioactive labeling of nanoparticles with albumin to study the biodistribution 
61 
 
The values correspondent to the figure 23 are in annex 2. The percentage of 
administered activity per mg in the stomach’s content is the maximum value, since it is the 
local of administration. The activity present in the organs and fluids beyond gastrointestinal 
tract is minimal. The activity present in the gastrointestinal wall has the higher values in the 
stomach’s wall. Related to the activity present in the stomach’s content, it decreases over 
time, however, the complete elimination is only seen 1440 minutes after the administration. 
The activity in the intestine’s content increases over the time and the 99mTc-BSA-NP 
progression and its elimination can be appreciated. The complete radiopharmaceutical 
elimination is only reached 1440 minutes after the administration.  
Figure 24 displays the percentage of administered activity per mg for each 
gastrointestinal wall for 360 minutes. 
 
Activity present in the stomach’s wall achieves the maximum value at 120 minutes after 
the administration with a marked decrease within 30 minutes. The higher activity in the 
duodenum’s wall is attained at 120 minutes after the administration. The same timings were 
obtained for the small intestine’s wall. At 360 minutes after the administration the 
radiopharmaceutical elimination is complete from the duodenum’s wall and the activity 
present in the small intestine’s wall achieves the minimal values. The large intestine’s wall has 
a peak of activity 120 minutes after the administration and at 360 minutes the complete 
radiopharmaceutical elimination was observed.   
Figure 24 - The percentage administered activity/mg of 99mTc-BSA-NP in the gastrointestinal wall. 
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The figure 25 shows the percentage of administered activity per mg in the content of 
each portion of gastrointestinal tract for 360 minutes. 
 
Activity present in the stomach’s content decreases over the time reaching a lower 
value around 360 minutes after the administration. The duodenum’s content achieves the 
activity peak 30 minutes after the administration with an elimination that reaches minimal 
values at 120 minutes. The peak of activity in the small intestine’s content is attained 90 
minutes after the administration whilst a lower value was obtained at 360 minutes. In the 
large intestine’s content, the maximum value occurs 180 minutes after the administration 
and at 360 minutes a considerable activity is present in its content.  
The organs and fluids beyond gastrointestinal tract were collected to study the intestinal 
absorption of 99mTc-BSA-NP. Related to this radiopharmaceutical, the liver and the kidneys 
show very small uptake, and the results are shown in the figure 26. 
Figure 25 - The percentage of administered activity/mg of 99mTc-BSA-NP in the gastrointestinal contents. 
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As shown in the figure 26 the uptake by the liver occurs 30 minutes after the 
administration and the uptake value is maintained for more 150 minutes, at least. At 360 
minutes after the administration no uptake is observed in liver. Ninety minutes after the 
administration is possible see activity in the kidneys that decreases after 30 minutes. 
The ROIs drawn in the cage images reveal a percentage of administered activity per mg 
equals to 0.0210(±0.0033) that corresponds to the eliminated contents (data not shown).  
3.4.4 Comparative study  
The purpose of the 99mTc-BSA biodistribution study is to compare it with the obtained 
for 99mTc-BSA-NP. Thus, next figures aimed to analyze differences between the profile of 
both radiopharmaceuticals.   
The figure 27 illustrates differences in the activity present in the stomach’s wall that are 
statistically significant until 180 minutes after administration. In fact, the p values obtained in 
the first 30 minutes and at 120 and 180 minutes after the administration were <0.001, and at 
90 min was <0.05. Values obtained 60 and 360 minutes after the administration reveal no 
differences. 
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Figure 26 - The percentage of administered activity/mg of 99mTc-BSA-NP in the liver and in the kidneys. 
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Figure 27 -  The percentage of administered activity/mg calculated in the stomach’s epithelium for 99mTc-BSA and 99mTc-
BSA-NP. For each time the percentage activity administered/mg of 99mTc-BSA was compared with the percentage activity 
administered/mg of 99mTc-BSANP. Significant differences are indicated by * corresponding to p<0.05 and *** p<0.001. 
 
In the duodenum’s wall, as shown in the figure 28, the radiopharmaceuticals behavior is 
similar showing differences statistically significant only for the values obtained at 120 and 180 
minutes after the administration (p<0.01 and p<0.001, respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28 - The percentage of administered activity/mg calculated in the duodenum’s epithelium for 99mTc-BSA and 99mTc-
BSA-NP. For each time the percentage activity administered/mg of 99mTc-BSA was compared with the percentage activity 
administered/mg of 99mTc-BSANP. Significant differences are indicated by ** corresponding to p<0.01 and *** p<0.001. 
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The figure 29 is related to the small intestine’s wall and the results show different 
statistical significance at the 30 and 60 minutes (p<0.05), 120 minutes (p<0.01) and 180 
minutes (p<0.05) after the administration.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29 - The percentage of administered activity/mg calculated in the small intestine’s epithelium for 99mTc-BSA and 
99mTc-BSA-NP. For each time the percentage activity administered/mg of 99mTc-BSA was compared with the percentage 
activity administered/mg of 99mTc-BSANP. Significant differences are indicated by * corresponding to p<0.05 and ** p<0.01 
 
 In the large intestine’s wall, that reflects the radiopharmaceuticals progression profile, 
and shown in the figure 30, there are statically significant differences only at 180 minutes 
after the administration (p<0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30 - The percentage of administered activity/mg calculated in the large intestine’s epithelium for 99mTc-BSA and 
99mTc-BSA-NP. For each time the percentage activity administered/mg of 99mTc-BSA was compared with the percentage 
activity administered/mg of 99mTc-BSANP. Significant differences are indicated by ** corresponding to p<0.01. 
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Figure 31 - The percentage of administered activity/mg calculated in the stomach’s content for 99mTc-BSA and 99mTc-BSA-
NP. For each time the percentage activity administered/mg of 99mTc-BSA was compared with the percentage activity 
administered/mg of 99mTc-BSANP. 
 
The figure 31 illustrates the absence of statistically significant differences between the 
radiopharmaceuticals on stomach’s contents. Similarly, in the duodenum’s contents, there 
are only statistically significant differences at 60 minutes after the administration (p<0.001), 
as can be seen in the figure 32.  
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Figure 32 - The percentage of administered activity/mg calculated in the duodenum’s content for 99mTc-BSA and 99mTc-BSA-
NP. For each time the percentage activity administered/mg of 99mTc-BSA was compared with the percentage activity 
administered/mg of 99mTc-BSA-NP. Significant differences are indicated by *** corresponding to p<0.001. 
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Figure 33 compare the results of the small intestine´s contents, and we can see that the 
radiopharmaceuticals elimination is similar, but showing statistically significant difference 
(p<0.001) for the 90 minutes after the administration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33 - The percentage of administered activity/mg calculated in the small intestine’s content for 99mTc-BSA and 99mTc-
BSA-NP. For each time the percentage activity administered/mg of 99mTc-BSA was compared with the percentage activity 
administered/mg of 99mTc-BSA-NP. Significant differences are indicated by *** corresponding to p<0.001. 
 
The large intestine’s contents elimination has statistically significant differences (p<0.01) 
only at 120 minutes after the administration, as illustrated in the figure 34. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34 - The percentage of administered activity/mg calculated in the large intestine’s content for 99mTc-BSA and 99mTc-
BSA-NP. For each time the percentage activity administered/mg of 99mTc-BSA was compared with the percentage activity 
administered/mg of 99mTc-BSA-NP. Significant differences are indicated by ** corresponding to p<0.01. 
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5. Discussion and Conclusions 
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NP have been considered for oral administration of several molecules, such as proteins, 
enzymes, drugs, by facilitating delivery and absorption in the target site and by stabilizing and 
ensuring biological activity when required during gastrointestinal transit (WILCZEWSKA, 
2012). The NP studied in this work are formulated by emulsification/internal gelation 
method in which nanoparticle contains a nucleus of calcium cross-linked alginate, dextran 
sulfate and insulin, following complexation with chitosan, being the outermost composed 
BSA. The BSA increases the stability of alginate-NP and consists of a protease-protective 
protein (HURTEAUX, 2005; SCHECHTER, 2005; WOITISKI, et. al., 2009a; WOITISKI, et. al., 
2009b).  
The aim of this work was to study the biodistribution of insulin-loaded BSA-coated NP. 
As their external coat is BSA, BSA was radiolabeled with 99mTc before coating NP. 
Therefore, BSA was radiolabed and a quality control procedure was developed and 
optimized. Another purpose of this study is the monitoring of NP while passing through 
gastrointestinal tract, namely contribute to better understand its degradation and 
mucoadhesive properties. Based on a comparison between the biodistribution studies 
obtained with the 99mTc-BSA and 99mTc-BSA-NP, some considerations are presented in this 
chapter.  
The development and optimization of BSA radiolabeling was the first step in which the 
optimization of the quality control procedure was the first approach in order to determine 
the radiochemical purity of 99mTc-BSA. Despite radiolabeling of HSA, namely with 99mTc has 
been studied, its quality control is poorly documented, in respect of 99mTc-RH quantification 
(ZOLLE, et. al., 1973; RHODES, 1974; KLEISNER, et. al., 2000; WANG, et. al., 2011). 
According to 99mTc-HSA quality control procedures available in literature and specifically 
concerning 99mTc-RH quantification there are two options of Rf value in the chromatographic 
systems in order to isolate 99mTc-RH. In the first option, it is possible to consider the Rf 
value of 99mTc-BSA different of zero and a 99mTc-RH Rf value equal to zero; in the second 
option it is possible to consider 99mTc-BSA Rf value equal to zero and a 
99mTc-RH Rf value 
different of zero. Based on this, and considering literature review, the mobile phase 
consisting of ACD was tested in different chromatographic strips in order to establish a 
quality control system in which the 99mTc-RH Rf value was different of zero (OZGUR, et. al., 
2011). As the stationary phase suggested by the literature was not available in Biophysics 
Department, other stationary phases were tested, namely Aluminum SG 60, Aluminum 
Oxide IB-F, ITLC-SG and Whatmman 31 ET. The chromatographic system with ACD as 
mobile phase and ITLC-SG as stationary phase resulted in a 99mTc-RH Rf value between 0.5 
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and 1, allowing the 99mTc-RH isolation. Thus it was possible to optimize the quality control of 
BSA radiolabeling with 99mTc in order to separate the possible impurities.  
In the end of the 60´s and beginning of the 70´s there were already several studies 
available with 99mTc-HSA. The radiolabeling procedure was largely studied, consequently 
there are several methods described (PERSSON and LIDÉN 1969; RHODES, 1974). Among 
these methods, the one that uses stannous chloride was the first choice, because it is widely 
used to prepare radiopharmaceuticals labeled with 
99m
Tc, and it is an easy, available and 
reproducible. The protocol that uses stannous chloride varies with the authors and the need 
of low pH during radiolabeling is not a prerequisite in all of them (WANG, et. al., 2011). For 
this reason, and due to the requirement of the NP coating be performed with a BSA solution 
at pH 5.1, firstly the radiolabeling procedure was performed with no pH manipulation and 
stannous chloride was dissolved in ultrapure water (the solution pH was 5.0). An higher 
radiochemical purity was achieved 30 minutes after the radiolabeling. However, the reaction 
is not stable over time and the percentage of 99mTc-RH rise up after 30 minutes.  
The 99mTc-RH formation occurs when a reduced 99mTc molecule undergoes hydrolysis in 
aqueous solution. In this case, reduced 99mTc reacts with water to form various hydrolyzed 
species depending on the pH, time duration of hydrolysis and presence of agents, like 
molybdenum and alumina. This hydrolysis competes with the chelation process of the 
desired compound and reduces the yield of 99mTc-pharmaceutical (SAHA, 2004a). These 
reactions turns more probable when stannous chloride is used in aqueous solution at pH of 
6.0 to 7.0. To prevent the hydrolysis of Sn2+, before the reduction of technetium, can be 
used an adequate quantity of reducing agent and besides that it is important to avoid the 
presence of oxygen, air, or any oxidizing agent in the vial (SAHA, 2004a). As the procedures 
were carried out in purgated vials and the stannous chloride was dissolved in purgated water 
the presence of oxygen was minimized. Furthermore, the antioxidant used to avoid 
radiolysis is widely described in the radiopharmaceutical preparation, such as for methylene 
diphophonate (MDP) and hydroxymethylenediphosphonic acid (HDP) kits whose cold kit 
formulation contains ascorbic acid (SAHA, 2004a). 
Taking in account the results obtained and the fact that ascorbic acid is used to stabilize 
the radiolabeling procedure and decrease the formation of 99mTc-RH, the effect of this 
organic acid was studied by using the stannous chloride method. However the results 
obtained were not satisfactory due to low radiochemical purity. Even in the case of the 
higher radiochemical purity there was always a disadvantage regarding the incubation time or 
the stability of the reaction. Also the effect of the heating in the protocol with ascorbic acid 
did not produce positive results. 
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Furthermore, the pH influence in the radiolabeling efficiency was also tested based on 
other methods described to label albumin with Tc-99m (PERSSON and LIDÉN, 1969; 
RHODES, 1974). The iron-ascorbic acid method requires low pH values, ranging between 1 
and 2 (PAOLI, et. al., 1966; PERSSON and LIDÉN, 1969; RHODES, 1974) whereby the pH 
values of 1 or 2 were tested in the previous protocol composed by stannous chloride and 
ascorbic acid. The radiolabeling efficiency with a pH = 1 seems be too low, because, although 
the reaction being stable its radiochemical purity is lower compared to the radiochemical 
purity obtained with pH = 2. Even though the positive influence of pH decrease in the 
radiochemical purity, which almost achieved 90 %, these results were difficult to reproduce, 
as referred in the bibliography (PERSSON and LIDÉN, 1969). 
Besides the methods with stannous chloride, a method that is described to prepare 
macroaggregates of HSA was also evaluated. The method consists in HSA radiolabeling with 
99mTc followed by heating at high temperature (90˚C), which promotes particles aggregation. 
Thus, this method was reproduced to radiolabel BSA without the last step in order to obtain 
a suspension of 99mTc-BSA particles (PAOLI, et. al., 1966; CRAGIN, 1969). The results of the 
radiochemical purity were the pretended since the percentage of radiolabeling was higher 
than 96 % and remain stable for 360 minutes, which fulfills the requirements to proceed to 
the in vivo studies. Taking into account that this protocol requires heating steps and pH 
changes, the best solution to prevent NP from this stress was coating them with 99mTc-BSA 
instead of radiolabeling the final NP. A further advantage of this procedure was mitigating the 
radiolabeling of other NP compounds allowing the comparative study between 
99mTc-BSA-NP and 99mTc-BSA biodistribution. However, even with the addition of a buffer 
solution with a pH of 7.4, the final pH of the solution was still too low (pH = 2). Thereby, 
the pH increase of 99mTc-BSA suspension was mandatory to allow efficient NP coating, since 
the isoelectric point of BSA is 4.7 (URBANO, 2004). The albumin coating of these NP is 
based in an electrostatic interaction with chitosan, which has a positive electric charge. 
Consequently, the BSA pH above isoelectric point is a requisite, since its functional groups 
must be negatively charged to interact with chitosan. Moreover, the NP coating at low pH 
could change the NP conformation since their polymeric matrix has pH-sensitive behavior. 
The pH variations affect the electric charge of insulin, which could be enough to decrease 
insulin entrapment (SARMENTO, et. al., 2007b; WOITISKI, et. al., 2009b). Since the influence 
of increasing pH to 5 after the radiolabeling of BSA was tested and no influence in the 
radiochemical purity was detected, the NP coating with 99mTc-BSA at this pH was possible. 
The NP formulation was optimized with a concentration of albumin adjusted according 
to several NP parameters, such as size, zeta potential and insulin entrapment. However, 
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during the production of NP, the percentage of albumin added to the NP suspension that 
actually interacts with the NP and the percentage that stays unbounded was unknown. 
Therefore, the available method to answer and solve this question was the centrifugation to 
separate the unbounded BSA combined with its quantification by Coomassie® Protein Assay 
Reagent Kit. This protocol revealed that a considerable percentage of BSA were not coating 
the NP since it was in the supernatant, after the coating step. The centrifugation protocol 
selected was the one with the lower time and rotation force applied capable of separate the 
maximum of unbounded BSA from the coated NP, in order to avoid aggregation, as much as 
possible. Therefore, the centrifugation was performed after the NP coating with 99mTc-BSA 
in order to eliminate the 99mTc-BSA that did not incorporate the nanoparticle, increasing the 
study specificity. Nevertheless, the NP sonication was carried out aiming the redispersion of 
NP in the suspension.  
According to the aim of this work, to study the biodistribution of insulin-NP and 
regarding the in vivo studies of NP was important to ensure the similarity between NP and 
radiolabeled NP, considering specific characteristics, like size distribution. Into this matter, 
working with radioactivity has some limitations, since it requires special conditions. To 
overcome this point the NP were coated with 99Tc-BSA, which maintain the chemical 
properties of 99mTc-BSA-NP. Thereby, size of either 99Tc-BSA-NP and BSA-NP was 
measured at the same conditions allowing the comparison. These results proved that 
radiolabeled BSA did not affect the NP characteristics, in respect of their size. However, 
other characteristics, such as  zeta potential and insulin entrapment efficiency should be 
determined to verify the influence of the protocol used to radiolabel NP did not affect its 
characteristics relatively to the original NP (SARMENTO, et. al., 2007a; SARMENTO, et. al., 
2007b; WOITISKI, et. al., 2009b).  
The in vivo studies were designed to ascertain the NP biodistribution, particularly in 
terms of gastrointestinal transit, since NP are intended for oral delivery. Taking in account 
that the nanoparticle radiolabeled constituent was BSA, the information obtained was 
specifically related with its biodistribution. However, the comparison of 99mTc-BSA and 
99mTc-BSA-NP biodistribution allows inferring about NP biodistribution based on the 
differences between the two radiopharmaceuticals.  
According to the NP purpose, the radiopharmaceuticals were administered by gavage. 
Besides the study with radiolabeled NP, the 99mTc-BSA biodistribution was also performed 
after gavage administration, in order to allow the comparison and to ensure the same 
conditions. Since the increase of pH is a requirement to coat NP, 99mTc-BSA was treated at 
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the same pH when administered to mice, to be possible to establish a correlation between 
both radiopharmaceuticals, which were in the same pH conditions. 
The information provided by the gastrointestinal contents allows to infer about times of 
gastrointestinal transit. The percentage of administered activity per mg for each 
gastrointestinal portion had tight differences, which reveals a time of gastrointestinal transit 
similar for both radiopharmaceuticals. The gastric empting for both radiopharmaceuticals is 
gradual over time, which is concordant with the normal pattern of gastric retention after 
gavage administration (LUCENA, 2009). 
The elimination of 99mTc-BSA-NP from the small intestine to the large intestine seems to 
be slower than 99mTc-BSA elimination, since the increase of activity in the large intestine is 
more gradual. Moreover, 90 minutes after the radiopharmaceuticals administration the 
activity present in the small intestine for 99mTc-BSA was around half of the activity present in 
the small intestine for 99mTc-BSA-NP (figure 33). In general, in humans, a molecule takes 
around 200 minutes to complete its intestinal progression after arrives to the cecum (KIM, 
1968; HUNG, 2006). The small intestine transit time for both radiopharmaceuticals, which 
reflects the intestinal progression, was between 90 and 120 minutes. Although the 
differences presented in their progression profiles, both achieved similar values of 
percentage of administered activity per mg in the small intestine’s contents at the same time. 
Taking into account that the metabolism of mice is faster than humans, these results seem to 
correspond to a normal transit time.   
The presence of the 99mTc-BSA-NP in the gastrointestinal wall reveals the NP adhesion 
properties. Contrary to what was observed in the gastrointestinal contents, the activity in 
the intestinal walls presented significant differences in the stomach, duodenum and small 
intestine, when the two radiopharmaceuticals, 99mTc-BSA and 99mTc-BSA-NP, are compared. 
The 99mTc-BSA present in the stomach wall in mice studied immediately after the 
administration was 70 % of its maximum value. This fact reveals a quickly retention of this 
radiopharmaceutical in the stomach epithelium. One hundred and twenty minutes after 
99mTc-BSA administration the activity present in the stomach wall roughly decreased 
comparing with the stomach wall activity observed 30 minutes before (90minutes after 
99mTc-BSA administration; figure 27). These results suggest that the radiopharmaceutical 
retention in the stomach wall was not proportional to the radiopharmaceutical present in 
the content, since the decrease of the percentage of administered activity per mg in this 
content was not so accentuated. The percentage of administered activity per mg in the 
stomach wall after 99mTc-BSA-NP administration only achieved the same higher values 
obtained by 99mTc-BSA immediately after the administration, 60 minutes after 99mTc-BSA-NP 
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administration (figure 27). Taking in account that the percentage of administered activities 
per mg in the first 30 minutes represent only 8 % of the maximum values obtained for 99mTc-
BSA-NP in the stomach wall and simultaneously the percentage of administered activities per 
mg of both radiopharmaceutical after 60 minutes are similar, it demonstrates that there is a 
possible late release of 99mTc-BSA from the 99mTc-BSA-NP, that has available to reach the 
stomach epithelium. According to stomach pH the albumin was positive electric charge. 
Therefore, the 99mTc-BSA release from the NP is based in charges repulsion, since the 
chitosan is positively charged (WOITISKI, et. al., 2009a). 
The percentage of administered activity per mg of 99mTc-BSA in the duodenum’s wall 
obtained 30 minutes after the administration was fairly near to the maximum peak value, 
remaining constant up to 90 minutes after the administration. The decrease of percentage of 
administered activity per mg of 99mTc-BSA in the duodenum’s wall revealed the same 
excretion profile of duodenum’s content. This fact suggests similarities on the behavior of 
99mTc-BSA in the duodenum content and wall. The values of percentage of administered 
activity per mg obtained in the study of 99mTc-BSA-NP in the duodenum’s epithelium was 
similar to the values obtained with 99mTc-BSA, since no significant differences were observed 
in the first 90 minutes of the study. However, the presence of 99mTc-BSA-NP in the 
duodenum’s wall was maintained in the same value until 180 minutes after the 
administration, contrary to the verified with 99mTc-BSA in which there was a decrease after 
90 minutes (figure 28). In other words, the presence of 99mTc-BSA-NP in the duodenum’s 
wall was maintained even after the radiopharmaceutical elimination from duodenum´s 
content, at 90 minutes. These results suggest that BSA maintain its interaction with NP or 
with NP constituents until 180 minutes after radiopharmaceutical administration. The 
adhesion of NP to the intestinal epithelium is expected according to the mucoadhesive 
properties of its constituents, namely, chitosan and alginate. The duodenum presents a basic 
pH, which triggers insulin release from NP according to the isoelectric point of insulin and 
its electrostatic interaction with alginate (SARMENTO, et. al., 2007a; SARMENTO, et. al., 
2007b; WOITISKI, et. al., 2009a; WOITISKI, et. al., 2009b). The BSA coating was designed to 
be a sacrificial-target in the stomach providing nanoparticle protection and avoiding the 
chitosan exposition to the stomach pH and consequently decreasing insulin release 
(WOITISKI, et. al., 2009a; WOITISKI, et. al., 2009b). BSA interaction with mucoadhesive 
polymers in the duodenum can explain the difference between the results obtained for the 
radiopharmaceuticals. At duodenum pH, the BSA interaction is probably with chitosan, since 
these compounds present opposite electrical charge, while the electrical charges of BSA and 
alginate are both negative. Actually, the values of percentage of administered activity per mg 
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in duodenum’s wall were very low, representing around 3 % of the maximum value obtained 
in the duodenum’s content (figure 28). Thus, even that the apparent BSA interaction with 
chitosan had influence on insulin retention, it would not compromise insulin release in 
duodenum, considering the low values of the 99mTc-BSA-NP present in the duodenum´s wall.   
The percentage of administered activity per mg of 99mTc-BSA in the small intestine’s wall 
has a peak 90 minutes after the radiopharmaceutical administration. The activity peak in the 
small intestine’s contents occured 60 minutes after the radiopharmaceutical administration, 
and in the next 30 minutes approximately half of the radiopharmaceutical moves to the large 
intestine (figures 29 and 33). These results suggest that the activity present in the wall was 
not proportional to the activity existent in the contents of the small intestine. Therefore, the 
results obtained with the small intestine’s wall could be explained by the radiopharmaceutical 
location along the small intestine. By other words, 90 minutes after the radiopharmaceutical 
administration the majority of the radiopharmaceutical present in the small intestine was in 
its distal portion. During the experimental work it was clear an alteration of the consistency 
of the intestinal content, what was related with the water absorption that occurs along the 
intestinal tract. Moreover, the high number of intestinal villus increases the intestinal 
epithelium surface, which can potentiate the radiopharmaceutical retention. The presence of 
intestinal villus allied to the more solid content consistency can justify the peak of activity 
present in the small intestine’s wall because both factors difficult the epithelium washing 
during biodistribution studies.  
The retention of 99mTc-BSA-NP in the small intestine’s wall reaches a percentage of 
administered activity per mg at 60 minutes that was maintained until 180 minutes after the 
administration. This radiopharmaceutical reached to the small intestine 30 minutes after the 
administration with a percentage of administered activity per mg in the small intestine’s 
content that surrounded 70% of the maximum value obtained to this content, although the 
peak only was 90 minutes after administration (figure 28). These results suggested that the 
radiopharmaceutical retention in the small intestine’s wall did not occur immediately after 
the radiopharmaceutical contact with the wall. Furthermore, the interaction between this 
radiopharmaceutical and this wall was maintained for the following 60 minutes, at least, after 
the radiopharmaceutical present in the content elimination to the large intestine. For the 
reasons mentioned above to the duodenum’s wall, these results suggested some interaction 
between BSA and chitosan that potentiate the radiopharmaceutical retention in the small 
intestine’s wall, even after the content progression. The values obtained in this wall are 
similar to the values obtained in the duodenum’s wall suggesting that the interaction 
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between BSA and chitosan are stable along the intestinal progression, although it only 
represents a little percentage of the administered radiopharmaceutical.  
The results obtained concerning large intestine’s wall and content were very similar for 
both radiopharmaceuticals, presenting the same profile (figure 29). Thus, the results 
suggested correlation between the presences of the radiopharmaceutical in the wall with the 
activity present in the content. The fact of the values of percentage of administered activity 
per mg obtained in the large intestine’s wall surrounded the triple of the values obtained in 
the other intestinal walls can be explained by the cecum anatomy and the consistency of the 
content, both for difficult the washing of the large intestine wall.  
The total elimination of both radiopharmaceuticals was supported by the absence of any 
counts in the static images acquired in the mice 1440 minutes after administration (figures 15 
and 16), and also because of the presence of activity in the feces existent in the cages, at the 
same time. The low values of the percentage of administered activity per mg obtained are 
explained by radionuclide decay, since 1440 minutes after the administration already passed 
four 99mTc half-times. Besides that and corroborating the results obtained for quality control 
it is possible to observe that there is no thyroid uptake (figures 19 and 23).  
Looking to the results obtained in the organs and fluids studied to evaluate the intestinal 
absorption at radiopharmaceuticals, the first consideration is focused in the fact that the 
values of the percentage administered per mg that are very low, surrounding 0.04% of the 
values obtained in the stomach’s content immediately after the administration. Thus, liver 
and kidney uptake was not significant.  
The obtained results reveal that the radiolabeling of BSA and BSA-NP with 99mTc and its 
quality control was optimized, since the radiolabeling efficiency obtained was higher than 
96 %, stable for 360 minutes and it was reproducible.  
Considering that albumin it is a sacrificial-target designed to protect the insulin-loaded 
NP in the stomach, the in vivo studies did not allow to conclude about the insulin absorption. 
A possible strategy to access this information is to label insulin with a radionuclide and 
through the nuclear medicine tools track its biodistribution after oral NP administration. 
According to the literature, the insulin has already been radiolabeled with single photons 
emitters, such as 67Ga, 123I and 99mTc, and with positron emitters, like 18F (DOZIO, 1992; 
AWASTHI, et. al., 1994; GUENTHER, et. al., 2006; JALILAN, 2007). 
Furthermore, considering the results observed and discussed, the differences between 
both radiopharmaceuticals suggested that not all of albumin was degraded in the stomach. 
Therefore, these results still give valid and fruitful information about NP transit in the 
gastrointestinal tract. Previous insulin release studies (data not shown) revealed that NP 
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achieved insulin total release 180 minutes after contact with simulated intestinal fluid. 
Moreover, considering that the in vivo studies reveal a time of small intestinal transit ranging 
between 90 and 120 minutes, a possible approach, to the nanoparticle optimization, was 
increase the permanency of NP in the small intestine.  
  
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
6. Bibliography
Radioactive labeling of nanoparticles with albumin to study the biodistribution 
 
83 
 
AKDOGAN, Y., REICHENWALLNER, J., HINDERBERGER, D. (2012). "Evidence for water-
tuned structural differences in proteins: an approach emphasizing variations in local 
hydrophilicity." Lister Hill National Center for Biomedical Communications. 
AL-TABAKHA, M. M., ARIDA, A. I. (2008). "Recent Challenges in Insulin Delivery Systems: 
A Review." Indian J Pharm Sci. 70(3):278-286. 
Alternative Devices for taking insulin in Diabetes guide today. Accessed on 23rd June 2014. 
Available on internet: http://diabetesguidetoday.com/alternative-devices-for-taking-
insulin/    
ARSHADY, R. (1990). "Albumin microspheres and microcapsules: methodology of 
manufacturing techniques." J. Control. Rel. 14: 111-131. 
AWASTHI, V. [et.al.] (1994). "99mTc—Insulin: Labeling, biodistribution and scintiimaging in 
animals." Nuclear Medicine and Biology 21(2): 251-254. 
BANERJEE, S., PILLAI, M. R., RAMAMOORTHY, N. (2001). "Evolution of Tc-99m in 
diagnostic radiopharmaceuticals." Sem Nucl Med 31(4): 260-277. 
BRANGE, J. (1987). Galenics of insulin: the physico-chemical and pharmaceutical aspects of 
insulin and insulin preparations, Springer-Verlag. 
BURTING, P. (2003). "Nutritional value of seaweeds." EJEAFChe 2: 498-503. 
CERNEA, S., RAZ, I. (2006). "Noninjectable methods of insulin administration." Drugs of 
Today 42(6):405. 
COLEMAN, R. E. (2006). Reimbursement for PET and PET/CT imaging. PET/CT - Essentials 
for Clinical Practice. R. E. WORKMAN, COLEMAN, R. R. USA, Springer: 23-32. 
CRAGIN, M. D., WEBBER, M. M., VICTERY, W. K., PINTAURO, D. (1969). "Technique for 
rapid preparation of lung scan particles using 99mTc-sulfur and human serum albumin." 
The journal of Nuclear Medicine 10: 621-623. 
CUI, F. [et.al.]. (2004). "A study of insulin-chitosan complex NP used for oral administration." 
j. Drug Del. Sci. Tech 14:435-439. 
DAMGÉ, C., VRANCKX, H. [et.al.] (1997). "Poly(alkyl cyanoacrylate) nanospheres for oral 
administration of insulin." Journal of Pharmaceutical Sciences 86(12): 1403-1409. 
DE PAOLI, T. [et.al.] (1966). "Albumin macroaggregates labelled with Tc99m." The 
International Journal of Applied Radiation and Isotopes 17(9): 551-552. 
DESCRITOFORO, C., ZOLLE, I. (2007). Quality control methods for 99mTc 
Radiopharmaceuticals. In: Zolle, I.. Technetium-99m Pharmaceutials: Preparations and 
Quality Control in Nuclear Medicine. Berlin, Springer. 123-149. 
Bibliography 
 
84 
 
DOZIO, N. [et.al.] (1992). "In vivo demonstration of insulin-receptor defect with 123I-
labeled insulin and scintigraphic scanning in severe insulin resistance." Diabetes Care 
15(5): 651-656. 
ELSINGA, P. [et.al.] (2010). Guidance on current good radiopharmacy parctice (cGRPP) for 
the small-scale preparation of radiopharmaceuticals E. J. N. M. M. Imaging, Springer. 
GEISS, M. M. E. A. L. S. (2000). The Burden of Diabetes Mellitus. In: N. G. C. JacK L. Leahy, 
William T. Cefalu.Medical Management of Diabetes Mellitus. New York, USA, Marcel 
Dekker, Inc. 1-17. 
GITTOES, N. J. L. [et.al.] (2010). Drug-Induced Diabetes. Textbook of Diabetes, Wiley-
Blackwell: 265-278. 
GOMBOTZ, W. R., WEE, S. F. (1998). "Protein release from alginate matrices." Adc. Drug 
Deliv. 31:267-285. 
GORDON STILL, J. (2002). "Development of oral insulin: progress and current status." 
Diabetes/Metabolism Research and Reviews 18(S1): S29-S37. 
GUENTHER, K. J. [et.al.] (2006). "Synthesis and in Vitro Evaluation of 18F- and 19F-Labeled 
Insulin:  A New Radiotracer for PET-based Molecular Imaging Studies." Journal of 
Medicinal Chemistry 49(4): 1466-1474. 
HANEMANN, T., SZABÓ, D. V. (2012). "Polymer-NP composites: from synthesis to 
modern application." materials 3:3468-3517. 
HOSNY, E. A., GHILZAI, N. M. K., AL-DHAWALIE, A. H. (1995). "Effective intestinal 
absorption of insulin in diabetic rats using enteric coated capsules containing sodium 
salicylate." Drug Dev. Ind. Pharm 21:1583-1589. 
How to give an insulin injection in Phartoonz, A cartoonized pharmacology! Accessed on 
23rd June 2014. Available on internet: http://www.phartoonz.com/2010/10/24/how-to-
give-an-insulin-injection/  
HUNG, G., TSAI, C., LIN, W. (2006). "Development of a new method for small bowel 
transit study." Annals of Nuclear Medicine 20(6): 387-392. 
HURTEAUX, R. [et.al.] (2005). "Coating alginate microspheres with a serum albumin-alginate 
membrane: application to the encapsulation of a peptide." Eur. J. Pharm. 24: 187-197. 
INTERNATIONAL ATOMIC ENERGY AGENCY, I. A. E. A. (2006). Quality assurance for 
Radioactivity Measurement in Nuclear Medicine. Technical reports series no. 454. I. A. 
E. A. Vienna: 19-32. 
JADVAR, H., PARKER, J. A. (2005). PET radiotracers. Clinical PET and PET/CT. H. JADVAR, 
PARKER, J. A. USA, Springer: 45-68. 
Radioactive labeling of nanoparticles with albumin to study the biodistribution 
 
85 
 
JALILAN, A. [et.al.] (2007). "Preparation and biodistributio of [67Ga]-insulin for SPECT 
purposes." Nukleonika 52(4): 145-151. 
JAWAHAR, N., MEYYANATHAN, SN. (2013). "Polymeric NP for drug delivery and 
targeting: A comprehensive review." International Journal of Health & Allied Sciences 
1(4):217-223. 
JUNG, T. [et.al.] (2000). "Biodegradable NP for oral delivery of peptides: is there a role for 
polymers to affect mucosal uptake?" Eur. J. Pharm. Biopharm. 50:147-160. 
KAYANI, I. [et.al.] (2008). "Functional imaging of neuroendocrine tumors with combined 
PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG." 
Cancer 112(11): 2447-2455. 
KIM, S. K. (1968). "Small intestine transit time in the normal small bowel study."  104(3). 
KLEISNER, I. [et.al.] (2000). The use of redox polymers in labelling procedures of proteins 
and peptides with 99mTc. I. Properties of redox polymers and technique of labelling. 
KNOWLER, P. H. B. A. W. C. (2005). Definition, Diagnosis, and Classification of Diabetes 
Mellitus and Glucose Homeostasis. In: L. W. Wilkins. Joslin's DIABETES MELLITUS. 
Boston, MA. 331-338. 
LENCKI, R. W. J., NEUFELD, R. J., SPINNEY, T. (1989). Method of producing microspheres. 
USA. 5:822-834. 
LENTLE, B., CELLER, A. (2003). An introduction to nuclear medicine. In: W. D. Leslie, 
Greenberg, I. D.Nuclear Medicine., Landes Bioscience. 1-14. 
LIU, X. D. [et.al] (2002a). "Preparation of uniform calcium alginate gel beads by membrane 
emulsification coupled with internal gelation." J. Appl. Polym. Sci. 87: 848-852. 
LIU, X. D. [et.al.] (2002b). "Characterization of structure and diffusion behavior of Ca-
alginate beads prepared with external or internal calcium sources." J. Microencapsul. 
19: 775-782. 
LIU, Y., TSENG, Y., HUANG, L. (2012). "Biodistribution studies of NP using fluorescence 
imaging: a qualitative or quantitative method?" Pharm Res. 29(12): 3273-3277. 
LUCENA, F. (2009). Desenvolvimento de radiofármaco para estudo não invasivo do trânsito 
intestinal. Master, Universidade de Lisboa. 
MAHAMOOD, A., JONES, A. (2003). Tehnetium Radiopharmaceuticals. Handbook of 
radiopharmaceuticals. Radiochemistry and application. M. Welch, Redvanly, C. West 
Sussex, John Wiley & Sons Ltd.: 323-362. 
MAHER, K. [et.al.] (2004). Basic Physics of Nuclear Medicine. In: K. e. a. MAHER, Wikibooks: 
63-93. 
Bibliography 
 
86 
 
McCONVILLE, P. [et.al.] (2013). "New learning: Advancing drug discovery and development 
through non-invasive biodistribution imaging." Molecular Imaging. 
Medtronic MiniMed Paradigm Insulin Pumps Lawsuit in Stainberg Law Firm P.C. Accessed on 
23rd June 2014. Available on internet: 
http://www.thesteinberglawfirm.com/medtronic/contact.htm 
ONAL, S., ZIHNIOGLU, F. (2002). "Encapsulation of insulin in chitosan-coated alginate gel 
beads: oral therapeutic delivery." Artif. Cells Blood Substit. Immobil. biotechnol. 
30:229-237. 
OPPENHEIM, R. C., [et.al.] (1982). "Production and evaluation of orally administered insulin 
NP." Drug Dev. Ind. Pharm 8:531-546. 
Ozgur, A. [et.al.] (2011). Synthesis and biological evaluation of radiolabeled photosensitizer 
linked bovine serum albumin NP as a tumor imaging agent. 
PEPPAS, N. A., KAVIMANDAN, N. J. (2006). "Nanoscale analysis of protein and peptide 
absorption: insulin using complexation and pH-sensitive hydrogels as delivery vehicles. 
." Eur. J. Pharm. Sci. 29:183-197. 
PERSSON, R. B. R. and K. LIDÉN (1969). "99mTc-labelled human serum albumin: A study of 
the labelling procedure." Int J Appl Radiat Isot 20(4): 241-248. 
Pharmjet introduces needle-free subcutaneous and intramuscular injectors in Gadget dite. 
Accessed on 23rd June 2014. Available on internet: 
http://www.gadgetlite.com/2010/11/10/pharmajet-introduces-needle-free/ 
PINTO REIS, C. [et.al.] (2006). "Nanoencapsulation II. Biomedical applications and current 
status of peptide and protein nanoparticulate delivery systems." Nanomedicine : 
nanotechnology, biology, and medicine 2(2): 53-65. 
PONCELET, D. (2001). "Production of alginate beads by emulsification/internal gelation." 
Ann. New York Acad. Sci. 944: 74-82. 
PONCELET, D. [et.al.] (1992). "Production of alginate beads by emulsification/internal 
gelation. I. Methology." Appl. Microbiol. Biotechnol. 38: 39-45. 
QI R, [et.al.] (2004). "Effect of casein and protamine on the enzymatic degradation and the 
orally hypoglycemic action of insulin." Acta Pharma Sin 39:844-848. 
RAJAONARIVONY, M. [et.al.] (1993). "Development of a new drug carrier made from 
alginate." J. Pharm. Sci 82: 912-917. 
REIS, C. P. [et.al.] (2008). "Nanoparticulate biopolymers deliver insulin orally eliciting 
pharmacological response." Journal of Pharmaceutical Sciences 97(12): 5290-5305. 
RHODES, B. A. (1974). "Considerations in the radiolabeling of albumin." Seminars in nuclear 
medicine 4(3): 281-293. 
Radioactive labeling of nanoparticles with albumin to study the biodistribution 
 
87 
 
SAHA, G. B. (2004a). Radipharmaceutical and Methods of Radiolabeling. Fundamentals of 
Nuclear Pharmacy. G. B. SAHA. New York, USA, Springer: 79-110. 
SAHA, G. B. (2004b). Instruments for Radiation Detection and Measurement. Fundamentals 
of Nuclear Pharmacy. G. B. SAHA. USA, Springer: 31-45. 
SAHA, G. B. (2004c). Quality Control of Radiopharmaceutials. In: G. B. SAHA.Fundamentals 
of Nuclear Pharmacy. USA, Springer. 152-174. 
SARMENTO, B. [et.al.] (2007b). "Oral Bioavailability of Insulin Contained in Polysaccharide 
NP." Biomacromolecules 8(10): 3054-3060. 
SARMENTO, B. [et.al.] (2007a). "Alginate/Chitosan NP are Effective for Oral Insulin 
Delivery." Pharmaceutical Research 24(12): 2198-2206. 
SCHECHTER, Y. [et.al.] (2005). "Albumin-insulin conjugate releasing insulin slowly under 
physiological conditions: a new concept for long-acting insulin." Bioconjug. Chem. 16: 
913-920. 
SELAM, J. L. (2010). "Evolution of Diabetes Insulin Delivery Devices." Journal of Diabetes 
Science and Technology 4(3): 505-513. 
SHARP, P. F., GOATMAN, K. A. (2005). Nuclear Medicine Imaging. In: P. SHARP, Gemmell, 
H. G., Murray, A. D.Pratical Nuclear Medicine. UK, Springer. 1-20. 
SHILPA, A., AGRAWAL, S. S., RAY, A. R. (2003). "Controlled delivery of drugs from alginate 
matrix." J. Macromol. Sci. 43:187-221. 
SILVA, C. M. [et.al.] (2006). "Insulin encapsulation in reinforced alginate microspheres 
prepared by internal gelation." Eur. J. Pharm. Sci. 29:148-159. 
SIMÕES, S. [et.al.] (2005). "Cationic hippodromes for gene delivery." Expert Opin. Drug 
Deliv. 2:237-25. 
SUBHASHINI, Y. (2013). "Insulin therapies: Current and future trends at dawn." World J 
Diabetes 4(1):1-7. 
TOUITOU, E., DONBROW, M., RUBINSTEIN, A. (1986). "Effective intestinal absorption of 
insulin in diabetic rats using new formulation approach." J. Pharm. Pharmacol. 32:108-
110. 
URBANO, A. [et.al.] (2004). Microencapsulação de fármacos peptídicos em pectina pelo 
métodos emulsificação/gelificação interna: a albumina como fármaco modelo. Master, 
Universidade de Coimbra. 
VANDENBERG, G. W., NOUÉ, J. D. L. (2001). "Evaluation of protein release from chitosan-
alginate microcapsules produced using external or internal gelation." J. Microencapsul. 
18: 433-441. 
Bibliography 
 
88 
 
WANG, Y. Chen [et.al.] (2011). "Technetium-99m-Labeled Autologous Serum Albumin: A 
Personal-Exclusive Source of Serum Component." Journal of Biomedicine and 
Biotechnology 2011. 
WANG, L. CHAN. [et.al.] (1997). "Effect of cellulose derivatives on alginate microspheres 
prepared by emulsification." J. Microencapsul. 14: 545-555. 
WANG, Y. CHIEN (1996). "Human Insulin: Basic Sciences to Therapeutic Uses." Drug 
Development and Industrial Pharmacy 22(8): 753-789. 
WANG, Y.F. [et.al.] (2007). "On-Site Preparation of Technetium-99m Labeled Human Serum 
Albumin for Clinical Application." The Tohoku Journal of Experimental Medicine 
211(4): 379-385.  
WILCZEWSKA, A. Z., NIEMIROWICZ, K., MARKIEWICZ, K. H., CAR, H. (2012). "NP as 
drug delivery systems." Pharmacological Reports 64: 1020-1037. 
WILD, S. [et.al.] (2004). "Global Prevalence of Diabetes: Estimates for the year 2000 and 
projections for 2030." Diabetes Care 27(5): 1047-1053. 
WILLIAMS, M. J. AND T. DEEGAN (1971). "The process inovolved in the binding of 
technetium-99m to human serum albumin." The International Journal of Applied 
Radiation and Isotopes 22(12): 767-774. 
WOITISKI, C. B. [et.al.] (2009a). Colloidal carrier integrating biomaterials for oral insulin 
delivery: Influence of component formulation on physicochemical and biological 
parameters. 
WOITISKI, C. B. [et.al.] (2009b). "Design for optimization of NP integrating biomaterials for 
orally dosed insulin." European Journal of Pharmaceutics and Biopharmaceutics 73(1): 
25-33. 
YOKOYAMA, A. [et.al.] (1975). "The role of ascorbic acid with the ferric ion in labelling 
human serum albumin with99 mTc." Int J Appl Radiat Isot 26(5): 291-299. 
ZOLLE, I. (2007). Technetium-99m Pharmaceuticals. Preparation and Quality Control in 
Nuclear Medicine. I. ZOLLE. Austria, Springer. 
ZOLLE, I. [et.al.] (1973). "Contribution to the study of the mechanism of labelling human 
serum albumin (HSA) with technetium-99m." The International Journal of Applied 
Radiation and Isotopes 24(11): 621-626. 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
7. Annex  
 
  
 
 
  
Radioactive labeling of nanoparticles with albumin to study the biodistribution 
 
91 
 
1 – Results of 99mTc-BSA biodistribution in % of administered activity/mg 
  
 0 min 
(mean±SD) 
30 min 
(mean±SD) 
60 min 
(mean±SD) 
90 min 
(mean±SD) 
120 min 
(mean±SD) 
180 min 
(mean±SD) 
360 min 
(mean±SD) 
1440 min 
(mean±SD) 
Stomach’s 
epithelium 
0.0029 
±0.0002 
0.0059 
±0.0004 
0.0245 
±0.0024 
0.0256 
±0.0016 
0.0347 
±0.0033 
0.0082 
±0.0004 
0.0046 
±0.0003 
0.0000 
±0.0000 
Stomach’s 
content 
0.5077 
±0.0109 
0.4452 
±0.0316 
0.3959 
±0.0859 
0.2691 
±0.0579 
0.1175 
±0.0308 
0.0427 
±0.0232 
0.0091 
±0.0064 
0.0000 
±0.0000 
Duodenu
m’s 
epithelium 
0.0000 
±0.0000 
0.0014 
±0.0003 
0.0024 
±0.0002 
0.0031 
±0.0008 
0.0032 
±0.0006 
0.0030 
±0.0006 
0.0000 
±0.0000 
0.0000 
±0.0000 
Duodenu
m’s 
content 
0.0000 
±0.0000  
0.1149 
(±0.0241  
0.0098 
(±0.0023  
0.0142 
(±0.0011  
0.0044 
(±0.0018  
0.0021 
±0.0007 
0.0004 
±0.0002 
0.0000 
±0.0000 
Small 
intestine´s 
epithelium 
0.0000 
 ±0.0000  
0.0003 
 ±0.0001  
0.0017 
 ±0.0004  
0.0019 
 ±0.0003  
0.0022 
 ±0.0005  
0.0021 
 ±0.0004  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
Small 
intestine’s 
content 
0.0000 
 ±0.0000  
0.1686 
 ±0.0396  
0.2335 
 ±0.0322  
0.2436 
 ±0.0268  
0.0387 
 ±0.0051  
0.0301 
 ±0.0057  
0.0022 
 ±0.0008  
0.0000 
 ±0.0000  
Large 
intestine’s 
epithelium 
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0030 
 ±0.0009  
0.0064 
 ±0.0010  
0.0043 
 ±0.0006  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
Large 
intestine’s 
content 
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.1047 
 ±0.0192  
0.1309 
 ±0.0275  
0.1624 
 ±0.0465  
0.0128 
 ±0.0020  
0.0000 
 ±0.0000  
Liver 0.0000 
 ±0.0000  
0.0001 
 ±0.0001  
0.0002 
 ±0.0001  
0.0002 
 ±0.0000  
0.0002 
 ±0.0000  
0.0002 
 ±0.0001  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
Lung 0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
Tyroid 0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
Muscle 0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
Blood 0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
Kidneys 0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0002 
 ±0.0001  
0.0002 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
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II – Results of 99mTc-BSA-NP biodistribution in % of administered activity/mg 
 0 min 
(mean±SD) 
30 min 
(mean±SD) 
60 min 
(mean±SD) 
90 min 
(mean±SD) 
120 min 
(mean±SD) 
180 min 
(mean±SD) 
360 min 
(mean±SD) 
1440 min 
(mean±SD) 
Stomach’s 
epitelium 
0.0262 
(±0.0009  
0.0273 
 ±0.0024  
0.0309 
 ±0.0079  
0.0367 
 ±0.0071  
0.0029 
 ±0.0007  
0.0020 
 ±0.0003  
0.0017 
 ±0.0006  
0.0000 
 ±0.0000  
Stomach’s 
content 
0.4989 
  ±0.0323  
0.3898 
 ±0.0320  
0.2705 
 ±0.0340  
0.2090 
 ±0.0542  
0.1407 
 ±0.0337  
0.0395 
 ±0.0126  
0.0084 
 ±0.0008  
0.0000 
 ±0.0000  
Duodenu
m’s 
epitelium 
0.0000 
 ±0.0000  
0.0019 
 ±0.0005  
0.0033 
 ±0.0003  
0.0021 
 ±0.0006  
0.0006 
 ±0.0001  
0.0004 
 ±0.0001  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
Duodenu
m’s 
content 
0.0000 
 ±0.0000  
0.0939 
  ±0.0170  
0.0462 
 ±0.0075  
0.0124 
 ±0.0028  
0.0028 
 ±0.0006  
0.0026 
 ±0.0005  
0.0020 
 ±0.0003  
0.0000 
 ±0.0000  
Small 
intestine´s 
epitelium 
0.0000 
 ±0.0000  
0.0006 
  ±0.0000  
0.0006 
 ±0.0001  
0.0021 
 ±0.0002  
0.0005 
 ±0.0001  
0.0002 
 ±0.0001  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
Small 
intestine’s 
content 
0.0000 
 ±0.0000  
0.1550 
 ±0.0236  
0.1987 
 ±0.0298 
0.0803 
 ±0.0105 
0.0249 
 ±0.0044 
0.0214 
 ±0.0015 
0.0015 
 ±0.0003 
0.0000 
 ±0.0000 
Large 
intestine’s 
epitelium 
0.0000 
 ±0.0000 
0.0000 
 ±0.0000 
0.0000 
 ±0.0000 
0.0028 
  ±0.0005 
0.0067 
 ±0.0005 
0.0018 
 ±0.0005 
0.0000 
 ±0.0000 
0.0000 
 ±0.0000 
Large 
intestine’s 
content 
0.0000 
 ±0.0000 
0.0000 
 ±0.0000 
0.0000 
 ±0.0000 
0.1523 
  ±0.0351 
0.2590 
 ±0.0359 
0.1486 
 ±0.0343 
0.0626 
 ±0.0059 
0.0000 
 ±0.0000 
Liver 0.0000 
 ±0.0000 
0.0000 
 ±0.0000 
0.0000 
 ±0.0000 
0.0000 
 ±0.0000 
0.0002 
 ±0.0001 
0.0002 
 ±0.0001 
0.0000 
 ±0.0000 
0.0000 
 ±0.0000 
Lung 0.0000 
 ±0.0000 
0.0000 
 ±0.0000 
0.0000 
 ±0.0000 
0.0000 
 ±0.0000 
0.0000 
 ±0.0000 
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
Tyroid 0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
Muscle 0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
Blood 0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
Kidneys 0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
0.0000 
 ±0.0000  
  
 
